US20230333043A1 - Solute-phase aptamer sensing with aptamer isolation - Google Patents
Solute-phase aptamer sensing with aptamer isolation Download PDFInfo
- Publication number
- US20230333043A1 US20230333043A1 US18/027,394 US202118027394A US2023333043A1 US 20230333043 A1 US20230333043 A1 US 20230333043A1 US 202118027394 A US202118027394 A US 202118027394A US 2023333043 A1 US2023333043 A1 US 2023333043A1
- Authority
- US
- United States
- Prior art keywords
- aptamer
- fluid
- analyte
- aptamers
- sensor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091023037 Aptamer Proteins 0.000 title claims abstract description 442
- 238000002955 isolation Methods 0.000 title claims abstract description 21
- 239000012530 fluid Substances 0.000 claims abstract description 199
- 239000012491 analyte Substances 0.000 claims abstract description 147
- 239000012528 membrane Substances 0.000 claims abstract description 110
- 239000000523 sample Substances 0.000 claims abstract description 62
- 230000027756 respiratory electron transport chain Effects 0.000 claims abstract description 44
- 230000008859 change Effects 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000012488 sample solution Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000011664 signaling Effects 0.000 claims description 85
- 239000000463 material Substances 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 12
- 238000004891 communication Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 239000010410 layer Substances 0.000 description 41
- 238000009792 diffusion process Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 26
- 239000000758 substrate Substances 0.000 description 22
- 230000008901 benefit Effects 0.000 description 21
- 239000000017 hydrogel Substances 0.000 description 16
- 229960000890 hydrocortisone Drugs 0.000 description 13
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 11
- 239000010931 gold Substances 0.000 description 11
- 238000002161 passivation Methods 0.000 description 11
- AKIZPWSPNKVOMT-UHFFFAOYSA-N 1-sulfanylhexan-1-ol Chemical compound CCCCCC(O)S AKIZPWSPNKVOMT-UHFFFAOYSA-N 0.000 description 10
- 229910052737 gold Inorganic materials 0.000 description 10
- 238000012546 transfer Methods 0.000 description 8
- 210000003722 extracellular fluid Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 210000004207 dermis Anatomy 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 229960000907 methylthioninium chloride Drugs 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000004365 square wave voltammetry Methods 0.000 description 4
- 238000004832 voltammetry Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000004082 amperometric method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PMBXCGGQNSVESQ-UHFFFAOYSA-N 1-Hexanethiol Chemical compound CCCCCCS PMBXCGGQNSVESQ-UHFFFAOYSA-N 0.000 description 2
- BIKSKRPHKQWJCW-UHFFFAOYSA-N 3,4-dibromopyrrole-2,5-dione Chemical compound BrC1=C(Br)C(=O)NC1=O BIKSKRPHKQWJCW-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000000970 chrono-amperometry Methods 0.000 description 2
- 238000001567 chrono-coulometry Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003869 coulometry Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 229960005191 ferric oxide Drugs 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002071 nanotube Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polypiperazine-amide Polymers 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000934858 Homo sapiens Breast cancer type 2 susceptibility protein Proteins 0.000 description 1
- 101000891683 Homo sapiens Fanconi anemia group D2 protein Proteins 0.000 description 1
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 229920000144 PEDOT:PSS Polymers 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100022033 Presenilin-1 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 229910001922 gold oxide Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001075 voltammogram Methods 0.000 description 1
- 239000003403 water pollutant Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3276—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a hybridisation with immobilised receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3277—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a redox reaction, e.g. detection by cyclic voltammetry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3278—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction involving nanosized elements, e.g. nanogaps or nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/4161—Systems measuring the voltage and using a constant current supply, e.g. chronopotentiometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/48—Systems using polarography, i.e. measuring changes in current under a slowly-varying voltage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Definitions
- Electrochemical aptamer sensors can identify the presence and/or concentration of an analyte of interest via the use of an aptamer sequence that specifically binds to the analyte of interest.
- These sensors include aptamers attached to an electrode, wherein each of the aptamers has a redox active molecule (redox couple) attached thereto.
- the redox couple can transfer electrical charge to or from the electrode.
- the aptamer changes shape, bringing the redox couple closer to or further from, on average, the electrode. This results in a measurable change in electrical current that can be translated to a measure of concentration of the analyte.
- a major unresolved challenge for aptamer sensors is the lifetime of the sensors, especially for applications where continuous operation is required (“continuous” referring to multiple measurements over time by the same device).
- continuous referring to multiple measurements over time by the same device.
- the flexibility of design is limited and often the sensitivity of the aptamer therefore suffers as a consequence.
- a sensing device for sensing an analyte in a sample fluid.
- the sensing device includes a sensor fluid including a plurality of aptamers, at least one or more of the aptamers being configured to sense an analyte included in a sample fluid (such as by binding thereto).
- the aptamer is freely diffusing in the sensor fluid.
- the sensing device further includes at least one isolation element that retains the plurality of aptamers in the sensor fluid.
- a method of fabricating a sensing device for sensing an analyte in a sample fluid includes defining a first volume configured to house a sample fluid with at least one analyte.
- the method further includes defining a second volume configured to house a sensor fluid, the sensor fluid including an analyte that is at least in part measured by an aptamer freely diffusing in the sensor fluid.
- the method further includes retaining the aptamer in the sensor fluid with at least one isolation element.
- a method of sensing an analyte in a sample solution includes bringing an analyte included in a sample fluid into contact with an aptamer included in a sensor fluid while the aptamer is freely diffusing in the sensor fluid.
- the contact of the aptamer with the analyte results in a change in the electron transfer between a redox tag and an electrode.
- the method further includes measuring the change in electron transfer between the redox tag and the electrode.
- FIG. 1 A is a cross-sectional view of a device in accordance with principles of the disclosed invention.
- FIG. 1 B is a cross-sectional view of an alternate embodiment of a device in accordance with principles of the disclosed invention.
- FIG. 2 A is a schematic showing a prior art portion of an aptamer sensor device having a passivating layer and an aptamer attached to an electrode.
- FIG. 2 B is a schematic showing the aptamer and passivating layer portions of the aptamer sensor device of FIG. 2 A degrading over time.
- FIG. 3 is a schematic of yet another embodiment of a device in accordance with principles of the present invention.
- FIG. 4 is a graph showing the effect of a membrane in an aptamer sensor device on percentage of solute retention versus molecular weight of the solute.
- FIG. 5 A is a schematic of yet another embodiment of a device in accordance with principles of the present invention.
- FIG. 5 B is a schematic showing an alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention.
- FIG. 5 C is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention.
- FIG. 5 D is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention.
- FIG. 5 E is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention.
- FIG. 6 A is a schematic of yet another embodiment of a device in accordance with principles of the present invention.
- FIG. 6 B is a schematic showing an alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention.
- FIG. 6 C is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention.
- FIG. 7 is a schematic of yet another embodiment of a device in accordance with principles of the present invention.
- FIG. 8 is a schematic of yet another embodiment of a device in accordance with principles of the present invention.
- FIG. 9 is a schematic of yet another embodiment of a device in accordance with principles of the present invention.
- FIG. 10 A is a graph showing raw chronoamperometric scans of current versus time for cortisol in an exemplary device.
- FIG. 10 B is a graph showing normalized current gain for three sensors versus concentration of cortisol.
- continuous sensing with a “continuous sensor” means a sensor that changes in response to changing concentration of at least one solute in a solution such as an analyte.
- continuous monitoring means the capability of a device to provide multiple measurements of an analyte over time.
- the term “about,” when referring to a value or to an amount of mass, weight, time, volume, pH, size, concentration or percentage is meant to encompass variations of in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
- electrode means any material that is electrically conductive such as gold, platinum, nickel, silicon, conductive liquid infused materials such as ionic liquids, PEDOT:PSS, conductive oxides, carbon, boron-doped diamond, nanotubes or nanowire meshes, or other suitable electrically conducting materials.
- blocking layer or “passivating layer” means a homogeneous or heterogeneous layer of molecules on an electrode which alter the electrochemical behavior of the electrode. Examples include a monolayer of mercaptohexanol on a gold electrode or as another example natural small-molecule solutes in serum that form a layer on a carbon electrode.
- aptamer means a molecule that undergoes a conformation or binding change as an analyte binds to the molecule, and which satisfies the general operating principles of the sensing method as described herein.
- Such molecules are, e.g., natural or modified DNA, RNA, or XNA oligonucleotide sequences, spiegelmers, peptide aptamers, and affimers. Modifications may include substituting unnatural nucleic acid bases for natural bases within the aptamer sequence, replacing natural sequences with unnatural sequences, or other suitable modifications that improve sensor function, but which behave analogous to traditional aptamers.
- aptamers bound together can also be referred to as an aptamer (i.e. not separated in solution).
- Aptamers can have molecular weights of at least 1 kDa, 10 kDa, or 100 kDa.
- redox tag or “redox molecule” means any species such as small or large molecules with a redox active portion that when brought adjacent to an electrode can reversibly transfer at least one electron with the electrode.
- Redox tag or molecule examples include methylene blue, ferrocene, quinones, or other suitable species that satisfy the definition of a redox tag or molecule.
- a redox tag or molecule is referred to as a redox mediator.
- Redox tags or molecules may also exchange electrons with other redox tags or molecules.
- the term “change in electron transfer” means a redox tag whose electron transfer with an electrode has changed in a measurable manner. This change in electron transfer can, for example, originate from availability for electron transfer, distance from an electrode, diffusion rate to or from an electrode, a shift or increase or decrease in electrochemical activity of the redox tag, or any other embodiment as taught herein that results in a measurable change in electron transfer between the redox tag and the electrode.
- fluorescent tag and “fluorescent quencher’ means molecules which are like those used in molecular beacon laboratory assays.
- fluorescent tags include 6-FAM (carboxylflourescien), JOE, TET, HEX, and examples of quenchers include black-hole quenchers, DABCYL.
- signal aptamer means an aptamer that is tagged with a redox active molecule or tag and/or contains a redox active portion itself and which provides a change in electrochemical signal when it is released from an anchor aptamer.
- anchor aptamer means an aptamer that that can bind to a signaling aptamer, and when bound to the signaling aptamer changes at least one property of the bound vs. unbound signaling aptamer such as molecular weight, diffusion coefficient, charge state, being floating in solution vs. being immobilized, or some other property which achieves the stated effect for the signaling aptamer.
- the binding of the anchor aptamer with the signaling aptamer is dependent on concentration of the analyte to be measured.
- folded aptamer means an aptamer that along its length associates with itself in one or more locations creating a three-dimensional structure for the aptamer that is distinct from an “unfolded aptamer” that is a freely floating and oscillating strand of aptamer. Aptamers can also be partially folded or partially unfolded in structure or in time spent in the folded vs. unfolded states. Multiple folding configurations are also possible.
- analyte means any solute in a solution or fluid which can be measured using a sensor.
- Analytes can be small molecules, proteins, peptides, electrolytes, acids, bases, antibodies, molecules with small molecules bound to them, DNA, RNA, drugs, chemicals, pollutants, or other solutes in a solution or fluid.
- membrane means a polymer film, plug of hydrogel, liquid-infused film, tiny pore, or other suitable material which is permiselective to transport of a solute through the membrane by solute parameters such as size, charge state, hydrophobicity, physical structure, or other solute parameters than can enable permiselectivity.
- solute parameters such as size, charge state, hydrophobicity, physical structure, or other solute parameters than can enable permiselectivity.
- a dialysis membrane is permselective by passing small solutes but not large solutes such as proteins.
- Membranes as understood herein need not be multiporous, for example a nanotube or nanopore can act as a permiselective filter and is therefore considered part of a membrane as understood for the present invention.
- sample fluid means any solution or fluid that contains at least one analyte to be measured.
- the term “sensor fluid” means a solution or fluid that differs from a sample solution by at least one property, and through which the sensor solution and the sample solution are therefore separated but are in fluidic connection through at least one pathway such as a membrane.
- the sensor solution comprises at least one aptamer as a solute.
- reservoir fluid means a solution or fluid that differs from a sample solution by at least one property, and through which the sensor solution and the reservoir solution are in fluidic connection through at least one pathway such as a membrane or a pin-hole connection.
- a reservoir fluid may have multiple function in a device, for example, by introducing a solute continuously or as needed by diffusion equilibrium into the sensor fluid, or for example removing unwanted solutes from a sensor fluid and acting as a “waste removal element”.
- a “device” comprises at least one sensor based on at least one aptamer, at least one sensor solution, and at least one sample solution.
- Devices can sense multiple samples and be in multiple configurations such as a device to measure a pin-prick of blood, or a microneedle or in-dwelling sensor needle to measure interstitial fluid, or a device to measure saliva, tears, sweat, or urine sensor, or a device to measure water pollutants or food processing solutes, or other devices which measure at least one analyte found in a sample solution.
- Sensors are preferably electrical in nature, but may also include optical such as a LED or laser excitation source and a photodetector, chemical, mechanical, or other known biosensing mechanisms. Sensors can be in duplicate, triplicate, or more, to provide improved data and readings. Sensors may provide continuous or discrete data and/or readings.
- Certain embodiments of the disclosed invention show sub-components of what would be sensing devices with more sub-components needed for use of the device in various applications, which are known (e.g., a battery, antenna, adhesive), and for purposes of brevity and focus on inventive aspects, such components may not be explicitly shown in the diagrams or described in the embodiments of the disclosed invention. All ranges of parameters disclosed herein include the endpoints of the ranges.
- FIGS. 1 A and 1 B exemplary embodiments of devices in accordance with principles of the disclosed invention are shown.
- a device 100 is shown as being placed partially in-vivo into the skin 12 of a subject.
- Skin 12 includes the epidermis 12 a , the dermis 12 b , and the subcutaneous or hypodermis 12 c .
- the device 100 includes a feature 112 that allows for access to sample fluids from the subject.
- sample fluids may include interstitial fluid (from the dermis 12 b ) and/or blood (from a capillary 12 d ).
- FIG. 1 A a device 100 is shown as being placed partially in-vivo into the skin 12 of a subject.
- Skin 12 includes the epidermis 12 a , the dermis 12 b , and the subcutaneous or hypodermis 12 c .
- the device 100 includes a feature 112 that allows for access to sample fluids from the subject.
- sample fluids may include interstitial fluid (from the
- the feature 112 includes a plurality of microneedles (which may be formed of metal, polymer, semiconductor, glass, or other suitable material). Each of the microneedles 112 projects from a first substrate 108 . And each microneedle 112 may include a hollow lumen 132 .
- the device 100 also includes a second substrate 110 (which may be a material such as polymer or glass) having an electrode 150 adjacent thereto.
- An optional passivating layer 120 may be adjacent to electrode 150 , such that electrode 150 is positioned between passivating layer 120 and second substrate 110 .
- Passivating layer 120 includes a compound such as mercaptohexanol or may comprise natural solutes that have diffused into the device 100 from the dermis 12 b.
- a defined volume 130 is present between first substrate 108 and passivating layer 120 . It will be recognized by those of ordinary skill in the art that defined volume 130 does not necessarily have to be defined by first substrate 108 and passivating layer 120 —and in embodiments where passivating layer is absent, volume 130 may be defined by first substrate 108 and electrode 150 ; or, alternatively, may be defined by first substrate 108 and second substrate 110 .
- a sensor fluid 18 may be present within volume 130 (as shown in FIG. 1 A ). Further, as can be seen in the embodiment of FIG. 1 A , at least one membrane 136 is present between first substrate 108 and passivating layer 120 , and is positioned adjacent first substrate 108 .
- the at least one membrane 136 may be of various materials or substances—such as a dialysis membrane or hydrogel, for example. In the particular embodiment shown in FIG. 1 A , portions of the membrane 136 overlie the boundary between volume 130 and lumens 132 of each microneedle 112 . Due to this positioning of membrane 136 , volume 130 includes sensor fluid 18 , and lumens 132 include sample fluid 14 —such as interstitial fluid from dermis 12 b or blood from capillary 12 d . Together the total volume provided by volume 130 and lumens 132 can be a microfluidic component such as channels, a hydrogel, or other suitable material. A diffusion or other fluidic pathway exists from the sample fluid 14 , such as interstitial fluid or blood, into volumes 132 , 130 .
- sample fluid 14 such as interstitial fluid or blood
- FIG. 1 B Another embodiment of a device 100 is shown in FIG. 1 B .
- This embodiment also includes first and second substrates 108 , 110 , microneedles 112 having lumens 132 , electrode 150 , passivating layer 120 , defined volume 130 and at least one membrane 136 .
- electrode 150 and passivating layer 120 are recessed in second substrate 110 (as opposed to the configuration shown in FIG. 1 A ).
- volume 130 is defined by first substrate 108 and combination of second substrate 110 and passivating layer 120 .
- the embodiment as shown in FIG. 1 B includes a plurality of membranes 136 , with each membrane 136 positioned in a distal end of each lumen 132 of each microneedle 112 . Due to this positioning of membranes 136 , both volume 130 and lumens 132 include a sensor fluid 18 (and sample fluid is present in, and obtainable from, dermis 12 b and capillary 12 d , for example).
- FIGS. 1 A and 1 B Alternative arrangements and materials to those discussed above with respect to FIGS. 1 A and 1 B are possible, such as using a single needle or hydrogel polymer microneedles.
- one or more of the features of device 100 or the entire device 100 could be implanted into the body and perform similarly as described herein.
- a device 100 could be fully outside the body, if for example sampling a fluid such as sweat or tears.
- an aptamer sensor includes a passivating or blocking layer 248 (including a compound such as mercaptohexanol) attached to an electrode 250 (made from a material such as gold), and having at least one aptamer 270 that is attached to the electrode 250 , such as by being thiol-bonded to the electrode 250 .
- the aptamer 270 has at least one redox tag or molecule 240 , such as methylene blue, associated therewith.
- the device 200 is shown as being positioned in a sample fluid 14 , such as blood or interstitial fluid (for example).
- This prior art device 200 may have an analyte (not shown) that binds with the aptamer 270 , thereby changing the availability of the redox tag 240 to the electrode 250 , such as by bringing it closer to, or further from, the electrode 250 .
- Conventional aptamer sensors can be limited in performance because an aptamer that is bound to an electrode often has a weaker binding affinity to an analyte than an aptamer that is free in solution.
- the sensors can degrade as the aptamer 270 and/or blocking layer 248 degrades over time (e.g., chemical degradation, or detaching from the electrode 250 ). Also, because such prior art devices 200 have relied on exogenous molecules (e.g., mercaptohexanol) for passivation, the passivation layer 248 can also become thicker with fouling from solutes (such as albumin) in the sample fluid 14 .
- solutes such as albumin
- FIG. 3 shows a device 300 (or at least a portion thereof) that includes an electrode 350 and at least one membrane 336 which separates a sample fluid 14 from a sensor fluid 18 .
- the sensor fluid 18 contains a plurality of aptamers 370 having redox tags 340 .
- the electrode 350 may include a passivating layer 348 .
- the passivating layer 348 may comprise one or more endogeneous solutes 16 from the sample fluid 14 itself (or, as initially prepared, the passivating layer 348 may be prepared from molecules that are known to be endogenous to the sample fluid to be tested).
- endogenous molecules 16 include small molecules such as amino acids, hormones, metabolites, or peptides.
- the device 300 shown in FIG. 3 differs from that described above in prior art FIGS. 2 A and 2 B in that the prior art device described above included an aptamer and an exogenous molecule, such as mercaptohexanol.
- electrode 350 could also contain a passivation layer 348 comprised, at least in part, by an exogenous molecule such as hexanethiol or mercaptohexanol. But, even in that case, the passivation layer could detach from the electrode 350 and be in need of replacement.)
- a passivation layer 348 comprised, at least in part, by an exogenous molecule such as hexanethiol or mercaptohexanol. But, even in that case, the passivation layer could detach from the electrode 350 and be in need of replacement.
- membrane 336 is able to pass in small solutes (e.g., ⁇ 1 kDa)—for example, an analyte such as cortisol—and passivating solutes 16 , such as amino-acids and peptides, but retains the aptamer 370 (with redox tag 340 ) which is often >10 kDa in molecular weight.
- aptamer 370 with redox tag 340 could be lost into the body and no longer able be able to provide a measurement of the analyte.
- FIG. 4 shows an illustrative plot of solute retention for a membrane such as membrane 336 .
- a membrane such as membrane 336 .
- This is an example only, and shows that if measuring a small analyte such as cortisol ( ⁇ 400 Da) and using a large aptamer (>10 kDa or even >50 kDa) a membrane could be highly permeable to the analyte and poorly permeable to the aptamer.
- membranes of the present invention may have molecular weight cutoffs (i.e., the molecular weight above which a molecule will not easily pass through the membrane) that are at least one of ⁇ 300 Da, ⁇ 1000 Da, ⁇ 3 kDa, ⁇ 10 kDa, ⁇ 30 kDa, ⁇ 100 kDa, ⁇ 300 kDa. Larger molecular weight cut-off membranes will require larger sized aptamers to prevent the aptamers from potentially escaping the device.
- an increase in availability of the redox tag to the electrode can occur as a result of aptamer binding analyte, or, alternatively, without aptamer binding to an analyte.
- the other the embodiments of the invention are not so limited (e.g., the various aptamer/redox tag types can be used across the various embodiments of devices disclosed herein, and vice versa.
- FIG. 5 A shows a portion of a device 500 including a substrate 510 , a sensor fluid 18 , a plurality of aptamers 570 with redox tags 540 free in the sensor fluid 18 , a passivation layer 548 of endogenous solutes 16 , and an electrode adjacent the substrate 510 .
- analytes 19 are also depicted as present in the sensor fluid of the device.
- the schematic shown in FIG. 5 A also depicts an electron transfer event that occurs between a redox tag 540 and the electrode 550 .
- aptamer binding to analyte can provide changes in electron transfer and redox current (compared to baseline transfer and current—i.e., transfer/current in the absence of analyte binding) of greater than 5%, greater than 10%, greater than 20%, greater than 50%, greater than 100%, or greater than 200%.
- electrical measurement techniques may include voltammetry, square wave voltammetry, amperometry, chronoamperometry, coulometry, chronocoulometry, with a preferred embodiment being square wave voltammetry.
- FIG. 5 B schematically depicts another example of an aptamer 570 with attached redox tag 540 (that differs from the aptamer 570 /redox tag 540 schematically shown in FIG. 5 A ).
- the embodiment of the aptamer 570 in FIG. 5 B is designed such that the redox tag 540 is more available for electron transfer with the electrode 550 in the absence of any analyte 19 binding to the aptamer 570 (high electron transfer—or high ET).
- the redox tag 540 is less available for electron transfer with the electrode 550 (e.g., the redox tag 540 is less exposed—low ET).
- FIG. 5 C schematically depicts yet another example of an aptamer with attached redox tag 540 (that differs from the aptamer 570 /redox tag 540 schematically shown in FIGS. 5 A and 5 B ).
- the embodiment shown in FIG. 5 C is designed with two aptamer portions: a signaling aptamer 572 and an anchor aptamer 574 .
- a redox tag 540 is associated with (such as by being attached to) the signaling aptamer 572 .
- the anchor aptamer 574 includes a portion that has affinity for, and thus can bind, analyte 19 . When analyte 19 is not bound to the anchor aptamer 574 (left side of FIG.
- the signaling aptamer 572 remains associated with the anchor aptamer 574 , and so the redox tag 540 on signaling aptamer 572 is less available for electron transfer with the electrode 550 (low ET).
- the anchor aptamer 574 binds to analyte 19 (right side of FIG. 5 C )
- signaling aptamer 572 is released from anchor aptamer 574 , and the redox tag 540 becomes more available for electron transfer with the electrode 550 (high ET).
- the device of the embodiment of FIG. 5 C has a plurality of aptamers—and thus includes a plurality of signaling aptamers 572 , and a plurality of anchor aptamers 574 .
- each anchor aptamer of the plurality of anchor aptamers is adapted to bind to analyte.
- each signaling aptamer of a majority of the plurality of signaling aptamers is bound to a respective anchor aptamer when a majority of anchor aptamers are not bound to any analyte. (This may occur, for example, prior to the introduction of any analyte.)
- analyte is introduced (such as when a sample fluid is introduced into the device—e.g., by being introduced into the sensor fluid of the device), at least a subset of anchor aptamers from the plurality of anchor aptamers then binds to analyte.
- a subset of signaling aptamers dissociates from the anchor aptamers—and the redox tag becomes more available for electron transfer with the electrode.
- analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer).
- signaling aptamer signaling aptamer having redox tag
- binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer).
- signaling aptamer 572 concentration will typically be less than or equal to the anchor aptamer 574 concentration else the signaling aptamer can cause increased background signal with or without the presence of analyte.
- FIG. 5 D schematically depicts yet another example of an aptamer with attached redox tag 540 (that differs from the aptamers/redox tags schematically shown in FIGS. 5 A, 5 B, and 5 C ).
- the embodiment of the aptamer 570 in FIG. 5 D has both a redox tag 544 and a redox quencher 542 associated therewith (such as by being bound to the aptamer 570 ).
- the redox tag 544 and redox quencher 542 are spatially separated (left side of FIG. 5 D ) thereby allowing for greater electron transfer between redox tag 544 and electrode 550 (high ET).
- the redox tag 544 and redox quencher 542 are brought into closer proximity with one another, thereby causing less electron transfer between redox tag 544 and electrode 550 (low ET).
- quenchers including anthraquinone-based redox molecules that can be self-quenching when two of such identical molecules are brought close together (monomer vs. dimer).
- FIG. 5 E schematically depicts yet another example of an aptamer with attached redox tag 540 (that differs from the aptamers/redox tags schematically shown in FIGS. 5 A, 5 B, 5 C , and 5 D).
- the embodiment of the aptamer 570 in FIG. 5 E has both a first redox tag 546 and a second redox tag 548 associated therewith (such as by being bound to the aptamer 570 ).
- the first and second redox tags 546 , 548 are spatially separated (left side of FIG.
- first and second redox tags 546 , 548 and electrode 550 high ET.
- the first and second redox tags 546 , 548 are brought closer together and the electron transfer from one of the redox tags 546 , 548 to the electrode 550 is altered due to a two-step mediated electron transfer process, or other effect, for two redox tags brought into close proximity.
- These changes in electron transfer are depicted in the voltammograms as shown as 546 a and 548 a .
- a non-limiting example of redox tags that enable the embodiment of FIG. 5 E include methylene blue and ferricyanide.
- FIG. 6 A shows a portion of a device 600 that includes a substrate 610 , at least first and second electrodes 650 , 652 , a passivation layer 648 including endogenous solutes 16 , a sensor fluid 18 (which, in the embodiment illustrated in FIG. 6 A is inside an optional hydrogel 638 ), a plurality of aptamers 670 having redox tags 640 (free in solution), and a diffusion or iontophoretic pathway 694 . Though not part of the device, analytes 19 are also depicted as present in the sensor fluid of the device.
- FIG. 6 A shows a portion of a device 600 that includes a substrate 610 , at least first and second electrodes 650 , 652 , a passivation layer 648 including endogenous solutes 16 , a sensor fluid 18 (which, in the embodiment illustrated in FIG. 6 A is inside an optional hydrogel 638 ), a plurality of aptamers 670 having redox tags 640 (free in solution
- FIG. 6 A also schematically depicts electron transfer that can occur between redox tags 640 and the first and second electrodes 650 , 652 .
- electron transfer 698 from the redox tags 640 in an increased amount, or frequency, or rate, when analyte 19 is bound to the aptamer 670 .
- the hydrodynamic radius or size of the aptamer is smaller and therefore providing a faster diffusion coefficient, which results in the redox tag being more available for electron transfer with the electrodes (such a version will be discussed in greater detail below with respect to FIG.
- the redox tag is not available—or is less available—to the electrode, due to, for example, a conformation of the aptamer that hinders or prevents such transfer when not bound to analyte; conversely, when aptamer binds analyte, the conformation of aptamer may change in a manner that positions the redox tag for electron transfer.
- aptamer binding to analyte can provide changes in electron transfer and redox current (compared to baseline transfer and current—i.e., transfer/current in the absence of analyte binding) of greater than 5%, greater than 10%, greater than 20%, greater than 50%, greater than 100%, or greater than 200%.
- electrical measurement techniques may include voltammetry, square wave voltammetry, amperometry, chronoamperometry, coulometry, chronocoulometry, with a preferred embodiment being amperometry.
- FIG. 6 B schematically depicts another example of an aptamer 670 with attached redox tag 640 (that differs from the aptamer 670 /redox tag 640 schematically shown in FIG. 6 A ).
- the embodiment of the aptamer in FIG. 6 B is designed such that the redox tag 640 is less available for electron transfer with the electrodes 650 , 652 in the absence of analyte binding to aptamer (left side of FIG. 6 B ), because of a longer diffusion time between the first and second electrodes 650 , 652 where the analyte can undergo redox recycling (e.g. one electrode is a reducing electrode, one electrode is an oxidizing electrode).
- analyte 19 binds to the aptamer 670 (right side of FIG. 6 B )
- the hydrodynamic radius or size of the aptamer is smaller and therefore providing a faster diffusion coefficient, and therefore redox tag 640 is more available for electron transfer with the first and second electrodes 650 , 652 .
- the binding of analyte 19 transforms the aptamer 670 between a long unfolded aptamer 670 (in the absence of analyte 19 binding) and an aptamer 670 with three stems when analyte 19 binds to aptamer 670 .
- a non-limiting example of an environment within a device 600 may include an optional hydrogel.
- the hydrogel 638 (such as agar or polyacrylamide) is added to further distinguish diffusion times between aptamers 670 bound to analyte 19 and aptamers 670 not bound to analyte. This is because the hydrogel 638 creates a more tortuous and size-selective diffusion pathway than a pure fluid would by itself.
- This equation is for diffusion in pure solution; a dense hydrogel 638 can be added to further distinguish the diffusion of the unfolded aptamer vs. the folded aptamer.
- the resulting current between the redox recycling electrodes is proportional as I ⁇ DC/z, where C is the concentration of the aptamer 670 and z the electrode-to-electrode distance.
- the diffusion length of oligonucleotides (aptamers) varies with length to the ⁇ 0.6th power, and a 15 kDa protein that is globular/unfolded can have a change in R of 2.15/3.65.
- FIG. 6 C schematically depicts yet another example of an aptamer 670 with attached redox tag 640 (that differs from the aptamer 670 /redox tag 640 schematically shown in FIGS. 6 A and 6 B ).
- the embodiment of the aptamer in FIG. 6 C is designed with two aptamer portions: a signaling aptamer 672 and an anchor aptamer 674 .
- a redox tag 640 is associated with (such as by being attached to) the signaling aptamer 672 .
- the anchor aptamer 674 includes a portion that has affinity for, and thus can bind, analyte 19 . When analyte 19 is not bound to the anchor aptamer 674 (left side of FIG.
- the signaling aptamer 672 remains associated with the anchor aptamer 674 , and so the redox tag 640 on signaling aptamer 672 is less available for electron transfer with the first and second electrode 650 , 652 (as the combined signaling and anchor aptamers 672 , 674 will exhibit slower diffusion in sensor solution and hydrogel).
- the anchor aptamer 674 binds to analyte 19 (right side of FIG.
- signaling aptamer 672 is released from anchor aptamer 674 , and the redox tag 640 becomes more available for electron transfer with the first and second electrodes 650 , 652 (as the liberated signaling aptamer 672 will exhibit more rapid diffusion in sensor solution and hydrogel). Further, while the embodiment shown in FIG.
- FIG. 6 C depicts analyte 19 binding to anchor aptamer 674 and redox tag 640 on signaling aptamer 672 , in an alternate embodiment analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer).
- each anchor aptamer of the plurality of anchor aptamers is adapted to bind to analyte.
- each signaling aptamer of a majority of the plurality of signaling aptamers is bound to a respective anchor aptamer when a majority of anchor aptamers are not bound to any analyte.
- analyte is introduced (such as when a sample fluid is introduced into the device—e.g., by being introduced into the sensor fluid of the device), at least a subset of anchor aptamers from the plurality of anchor aptamers then binds to analyte.
- a subset of signaling aptamers from the total plurality of aptamers dissociates from the anchor aptamers—and the redox tag becomes more available for electron transfer with the electrode.
- This diffusion time to an electrode may also impact interrogation methods such as square wave voltammetry, as aptamer that is near the electrode can contribute to the signal as well if it is able to diffuse to the electrode during each square window (during each voltage pulse that is applied).
- the first and second electrodes 650 and 652 can be closely spaced via interdigitation or other suitable technique, and, in such an embodiment, may be within less than 50 ⁇ m, less than 10 ⁇ m, less than 2 ⁇ m, or less than 0.4 ⁇ m distant of each other.
- FIG. 7 a portion of a device 700 is shown, and includes a substrate 710 , at least one electrode 750 , a passivation layer 748 including endogenous solutes 16 , a sensor fluid 18 , a plurality of aptamers having redox tags 740 (free in the sensor solution), and a poorly-mobile or non-mobile material 738 in the sensor fluid 18 .
- analytes 19 are also depicted as present in the sensor fluid of the device.
- the aptamers/redox tags component of the embodiment of FIG. 7 is similar to that shown in FIGS. 5 C and 6 C , and includes two aptamer portions: a signaling aptamer 772 and an anchor aptamer 774 .
- a redox tag 740 is associated with (such as by being attached to) the signaling aptamer 772 .
- the anchor aptamer 774 includes a portion that has affinity for, and thus can bind, analyte 19 .
- the anchor aptamer 774 is immobilized via linkage 739 to the poorly or non-mobile material 738 .
- the poorly-mobile or non-mobile material 738 may comprise various materials, such as a hydrogel.
- the material 738 could be a hydrogel such as polyacrylamide and the linker be a molecule such as acrydite that is attached to the anchor aptamer at a terminal end or other location.
- the anchor aptamer could be cross-linked with other anchor aptamers or the anchor aptamer made so large (e.g., >100 kDa) such that it is effectively immobile in a dense hydrogel 738 .
- the signaling aptamer 772 remains associated with the anchor aptamer 774 , and so the redox tag 740 on signaling aptamer 772 is less available for electron transfer with the electrode 750 (because the combined signaling and anchor aptamers 772 , 774 will be poorly-mobile or non-mobile in the sensor fluid due to anchor aptamer 774 being linked to material 738 ).
- the signaling aptamer 772 is released from anchor aptamer 774 (as indicated by arrow 796 ), and the redox tag 740 becomes more available for electron transfer with the electrode 750 (because the liberated signaling aptamer 772 will exhibit more rapid diffusion in sensor solution as it is no longer complexed with the anchor aptamer 774 that is linked to poorly-mobile or non-mobile material 738 ). Further, while the embodiment shown in FIG.
- analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer).
- the device of the embodiment of FIG. 7 has a plurality of aptamers—and thus includes a plurality of signaling aptamers 772 , and a plurality of anchor aptamers 774 .
- each anchor aptamer of the plurality of anchor aptamers is adapted to bind to analyte.
- each signaling aptamer of a majority of the plurality of signaling aptamers is bound to a respective anchor aptamer when a majority of anchor aptamers are not bound to any analyte.
- analyte is introduced (such as when a sample fluid is introduced into the device—e.g., by being introduced into the sensor fluid of the device), at least a subset of anchor aptamers from the plurality of anchor aptamers then binds to analyte.
- a subset of signaling aptamers from the total plurality of aptamers dissociates from the anchor aptamers—and the redox tag becomes more available for electron transfer with the electrode.
- FIG. 8 With reference to FIG. 8 , where like numerals refer to like features, another embodiment in accordance with aspects of the present invention is shown. As can be seen in FIG. 8 , a portion of a device 800 is shown, and includes a substrate 810 , at least one electrode 850 , a membrane 838 , a sensor fluid 18 , a plurality of aptamers having redox tags 740 (free in the sensor fluid). Though not part of the device, analytes 19 are also depicted as present in the sensor fluid of the device.
- the aptamers/redox tags component of the embodiment of FIG. 8 is similar to that shown in FIGS.
- a redox tag 840 is associated with (such as by being attached to) the signaling aptamer 882 .
- the anchor aptamer 884 includes a portion that has affinity for, and thus can bind, analyte 19 .
- the membrane 838 exhibits selective permeability based on size, charge, or at least one solute property, and is able to pass a signaling aptamer 882 but not a signaling aptamer that is attached to a larger anchor aptamer 884 . Thus, the membrane 838 impacts the availability of the redox couple 840 to the electrode 850 .
- a signaling aptamer could have a radius of 3 nm/2 nm in folded/unfolded states and an anchor aptamer have 27/7 nm in folded/unfolded state, creating a difference in size of ⁇ 3-10 ⁇ when a signaling aptamer is freed from an anchor aptamer.
- Nanofiltration membranes can provide 1s nM pore sizes, and ultrafiltration 10s to 100s nm pore sizes (PES, track-etch, and other materials), resulting in size selective permeability that would enable mainly only the signaling aptamer 882 to penetrate the hydrogel or membrane 838 .
- the signaling aptamer 882 is released from anchor aptamer 884 and is able to pass through membrane 838 , resulting in the redox tag 840 becoming available for electron transfer with the electrode 850 . Further, while the embodiment shown in FIG.
- analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer).
- a membrane is used to selectively allow passage of certain molecules and not of others.
- aptamers and redox tags can degrade over time, it may be advantageous to continually introduce a fresh supply of aptamers, signaling aptamers, and/or anchor aptamers or other solutes that increase performance of the sensor or improve longevity of the sensor (e.g. nuclease inhibitors, for example).
- a portion of a device 900 includes substrates 910 , at least one electrode 950 , a membrane 936 , a sample fluid 14 , a sensor fluid 18 , and a reservoir fluid 17 .
- the membrane 936 exhibits mass flow represented at reference numeral 991
- the device also includes a diffusion restrictive feature 935 (such as a pinhole or membrane) with a mass flow represented at reference numeral 993 .
- aptamers are 10-100 ⁇ larger than the solute to be detected (e.g., phenylalanine, cortisol, etc.).
- volume of reservoir fluid 17 is at least one of 2 ⁇ , 10 ⁇ , 50 ⁇ , or 250 ⁇ greater than volume of sensor fluid 18 and that the mass flow 991 of aptamer is at least 2 ⁇ , 10 ⁇ , 50 ⁇ , or 250 ⁇ less than mass flow 993 of aptamer, while the mass flow 991 of the analyte is at least 2 ⁇ , 10 ⁇ , 50 ⁇ , or 250 ⁇ greater than the mass flow 993 of the analyte.
- the concentrations of analyte will be within at least 50%, 10%, 2%, or 0.4% of each other when comparing sample fluid 14 with sensor fluid 18
- the concentrations of aptamer will be within at least 50%, 10%, 2%, or 0.4% of each other when comparing sensor fluid 18 and reservoir fluid 17 .
- Aptamers could also degrade over time and their presence in the device and the presence of other contaminants such as nucleases or proteins could be problematic. For example, if signaling aptamers became cleaved and their molecular weight decreased, they could give a false higher reading of signal in embodiments of the present invention. With membrane protection of the sensor fluid from the sample fluid, most degradation or contamination modes will be very slow, such that the reservoir may also act as a waste removal element.
- FIG. 9 various aspects of the present invention are taught in greater detail with respect to isolation of aptamer (or the plurality of aptamers) in the sensor fluid 18 from the sample fluid 14 and reservoir fluid 17 .
- the principles described with respect to FIG. 9 apply broadly to other embodiments of devices disclosed herein.
- an aptamer sensor for creatinine or phenylalanine (which have molecular weight of only 131 Da and 165 Da, respectively), and an aptamer having a molecular weight of 10-15 kDa (which is common for many aptamers).
- a membrane 936 having a 150 Da molecular weight cutoff could be used to prevent movement of aptamers from sensor fluid to another fluid (like sensor fluid to sample fluid).
- commercial membranes such as Dow FilmTech Polyamide membranes with 200-400 Da cutoffs may be suitable for use as membrane 936 .
- non-limiting examples of alternate materials for the membrane 936 include cellulose acetate, polypiperazine-amide, and polydimethylsiloxane. But even in such a case, conventional membranes are designed for pressure-driven separations, and so include a significant thickness or a backing layer, which increases overall thickness (on the order of 100s of ⁇ M).
- the membrane backing material can be facing the sample fluid 14 to resolve this lag time increase at least in part because backing material typically has high porosity.
- the thickness or porosity of the membrane 936 can be adjusted easily.
- the present invention may benefit from a membrane 936 that has a Deff/Ax of, in one embodiment, at least 5 m s ⁇ 1 ⁇ 10 ⁇ 3 .
- the Deff/Ax is at least 0.5 m s ⁇ 1 ⁇ 10 ⁇ 3 .
- the Deff/Ax is at least 0.05 m s ⁇ 1 ⁇ 10 ⁇ 3 .
- the Deff/Ax is at least 0.005 m s ⁇ 1 ⁇ 10 ⁇ 3 .
- Membranes 936 of the present invention are, in one embodiment, less than about 100 nm thick. In another embodiment, membranes of the present invention are less than 1 ⁇ m thick.
- membranes of the present invention are less than 10 ⁇ m thick. In another embodiment, membranes of the present invention are less than 100 ⁇ m thick.
- a membrane 936 with a well-designed Deff/ ⁇ x of at least 5 m s ⁇ 1 ⁇ 10 ⁇ 3 and thickness of sensor fluid 18 of ⁇ 1-10 ⁇ m, can enable a device on/off time for the sensor to measure 90% of the sample fluid concentration in at least ⁇ 15 min.
- the analyte molecular weight will become larger or be too large to permeate the membrane 936 , and the aptamer might permeate the membrane 936 due to its molecular weight or due to a stranded geometry that allows it to navigate through a membrane similar to a rope being pulled or pushed through a screen (if the rope were balled up, it could not be pushed through the screen). Therefore, alternate methods of isolating the aptamer from sample fluid 14 are needed in some cases.
- One important factor is the retention % vs. molecular weight, (see the graph for a membrane 936 as illustrated in FIG. 4 ). This is also referred to as retentivity.
- a typical membrane 936 can provide >90% retention for example at 10 kDa, and ⁇ 9% retention at ⁇ 1 kDa for a change in retentivity/change in molecular weight of ⁇ 1 ⁇ .
- This is not highly selective with respect to the present invention, because for example, with an implanted device, aptamers could be slowly and continually lost over time. Therefore, the present invention may benefit from a membrane with a change in retentivity/change in molecular weight that, in one embodiment, is at least 2 ⁇ .
- the membrane has a change in retentivity/change in molecular weight that is at least 5 ⁇ .
- the membrane has a change in retentivity/change in molecular weight that is at least 10 ⁇ .
- the membrane has a change in retentivity/change in molecular weight that is at least 20 ⁇ .
- the volume of sensor fluid 18 could be 1 ⁇ L in volume using an area of membrane 936 of 0.1 cm 2 and a separation distance between membrane 936 and electrode 950 of 0.01 cm (100 ⁇ m).
- a reservoir, including reservoir fluid 17 which in turn includes fresh aptamer solution could be in fluid communication with the volume including sensor fluid 18 via a pore 995 that is only 0.001 cm 2 , such that analyte and aptamer would very slowly diffuse into/out of the aptamer reservoir, again, shown in FIG. 9 as including reservoir fluid 17 , but such that new aptamer would constantly diffuse into the volume including the sensor fluid 18 as any aptamer is lost from the sensor fluid 18 through the membrane 936 to the sample fluid 14 .
- the pore 995 is a fluidic connection from the reservoir, including the reservoir fluid 17 , and the volume, including the sensor fluid 18 .
- Such an approach could allow for protein sensing. For example, assume a sensor fluid 18 volume of 100 nL, and a membrane 936 that retains 90% of the aptamer over 6 hours, and which can allow a protein such as luteinizing hormone to diffuse into the sensor fluid 18 and achieve 90% of sample fluid 14 concentration of the hormone within 12 hrs. This would allow a device 900 to sufficiently measure luteinizing hormone for fertility monitoring applications. Now, if the reservoir including reservoir fluid 17 with aptamer had a volume of 200 ⁇ L, then it could lose 10% of its aptamer before a sensor signal would be impacted by 10%.
- the device 900 If the device 900 is losing aptamer through the membrane 936 at a rate of, for example, 10% of aptamer every 6 hours in the 100 nL volume including sensor fluid 18 , then with the 200 ⁇ L reservoir including reservoir fluid 17 , the device 900 could last 2000 ⁇ longer or 12,000 hours or >16 months, more than long enough for creating an implantable device 900 . Therefore, depending on the volume of the reservoir including reservoir fluid 17 and scaling of other device 900 dimensions and membrane 936 porosity, the present invention can retain 90% of the initial aptamer concentration in the sensor fluid 18 for at least >16 months, >8 months, >4 months, >2 months, >1 month, >2 weeks or >1 week.
- the aptamer is designed such that one end of the aptamer is inactive and increases the total molecular weight of the aptamer by at least 50%.
- the aptamer includes an active end configured to bind to the analyte and which has the redox tag.
- the aptamer may include a longer inactive end configured to provide molecular weight or size to the aptamer and/or configured to reduce aptamer permeation through the membrane 936 .
- the longer inactive end may be configured to be rigid or have at least one permanent fold, wherein the rigid aptamer or aptamer including a permanent fold is dimensionally larger than a non-rigid aptamer or aptamer not including a permanent fold.
- the molecular weight of such aptamers is at least >15 kDa.
- the molecular weight of such aptamers is at least >30 kDa.
- the molecular weight of such aptamers is at least >60 kDa.
- the molecular weight of such aptamers is at least >120 kDa.
- active end aptamer could have a molecular weight of at least ⁇ 20, ⁇ 10, or ⁇ 5 kDa, and the inactive end of the aptamer may be configured to be folded and therefore configured to increase the total size and molecular weight of the aptamer.
- aptamers may be attached to other materials, or to nanoparticles, to also help isolate them from the sample fluid.
- an aptamer could be attached to a polyethylene glycol polymer, the polyethylene glycol polymer may have a molecular weight of about 300 kDa, which can be referred to as a ‘particle’.
- Particles could be other polymers, metal such as gold, carbon, or iron-oxide and can be, in different embodiments, at least >1 nm, >3 nm, >10 nm, >30 nm, or >100 nm in diameter and still stably dispersed in solution as is known using one or more methods like those used in the art of pigment and nanodispersions.
- Aptamers can be bound to iron nanoparticles using, as a non-limiting example, dibromomaleimide (DBM)-termination, and bound to gold nanoparticles using thiol termination.
- the aptamer isolation element may also be a magnet that retains the nanoparticles near the membrane with or without use of a membrane, and in this example the aptamer isolation element is a magnet. This approach could allow the present invention to measure a protein analyte, for example a 30 kDa protein with an average diameter of ⁇ 5 nm.
- the aptamers may be optically tagged aptamers having a fluorescent tag.
- a fluorescence quencher may be used as well.
- layer 120 could be a semi-transparent light source such as organic light emitting diode and electrode 150 could be a light detector such as an inorganic photodiode facing the sample fluid with or without a light filter to increase signal to noise ratio.
- Aptamer could be tagged with a fluorescent optical tag that is excited by the light source 120 and then emits light that is detected by the electrode 150 .
- the present invention may also include a fluorescence quencher that is tagged to the aptamer such as a black-hole quencher.
- the analyte itself is the fluorescence quencher (e.g. NADH, FAD, elastin, collagen, tryptophan, keratin) by absorbing the energy from the fluorescence tag and emitting the light at a wavelength different than the fluorescence tag.
- the fluorescence quencher e.g. NADH, FAD, elastin, collagen, tryptophan, keratin
- a typical optical aptamer probe is 25 nucleotides long. 15 of the nucleotides are complementary to or have a strong binding affinity for the analyte target and do not base pair with one another, while the five nucleotides at each terminus are complementary to each other rather than having strong affinity to the target analyte.
- a typical molecular beacon structure can be divided in 4 parts: 1) loop, an 18-30 base pair region that is complementary to or has strong binding affinity for the target analyte; 2) stem formed by the attachment to both termini of the loop of two short (5 to 7 nucleotide residues) oligonucleotides that are complementary to each other; 3) 5′ fluorophore at the 5′ end of the aptamer, a fluorescent dye is covalently attached; 4) 3′ quencher (non-fluorescent) dye that is covalently attached to the 3′ end of the aptamer. When the aptamer is in closed loop shape, the quencher resides in proximity to the fluorophore, which results in quenching the fluorescent emission of the latter.
- the fluorescence tag and quencher can experience an average change in their distance with analyte binding, similar to that taught in previous embodiments of the present invention where a redox tag experiences an average change in distance to an electrode surface.
- the sensor fluid 18 and/or reservoir fluid 17 contains a passivating solute such as peptides (e.g., albumin) that can continually re-attached to the electrode and support a long-lasting and predictable passivating layer.
- a passivating solute such as peptides (e.g., albumin) that can continually re-attached to the electrode and support a long-lasting and predictable passivating layer.
- albumin may exist in the sample fluid 14 , it may be unable to reach the sensor fluid 18 due to the membrane 936 .
- the embodiments of the present invention may also be applied to a simple single-use device.
- device 100 of FIG. 1 could be applied to the skin 12 and take a single measurement of an analyte within 15 minutes of application of the device 100 and then removed from the skin 12 surface.
- a device format similar to a glucose test-strip or other device with a microfluidic channel or a wicking channel can be used to transport a sample fluid to one or more sensors and embodiments as taught herein for the present invention.
- the aptamers and redox tags could be dry and placed near the inlet of such a test strip and dissolved into the sample fluid and then transported to a membrane-protected working electrode where measurement of the analyte is performed.
- a cortisol binding aptamer was utilized in a manner similar to that taught in FIG. 6 C , where the signaling aptamer 672 was tagged with methylene blue as a redox tag 640 with an aptamer sequence of GTCGTCCCGAGAG [SEQ ID NO. 1] and where the anchor aptamer 674 with a sequence of ctctcgggacgacGCCCGCATGTTCCATGGATAGTCTTGACTAgtcgtcccc [SEQ ID NO. 2].
- Electrodes 650 , 652 were gold interdigitated electrodes with a 5 ⁇ m spacing in between them. The gold electrodes were passivated with an exogenous molecule of mercaptohexanol. No hydrogel 638 was utilized in this experiment.
- the sensor solution was buffer solution with 5 ⁇ M of the aptamers 650 , 652 in solution, and a reference electrode of platinum was used.
- the device 600 was measured amperometrically vs. a titration curve of cortisol as the analyte 19 . The results are shown in FIG. 10 A and FIG.
- Example 1 The signal gain in Example 1 is as much as 70%, and if the anchor aptamer was made even larger or smaller the signal gain could be tuned to be as much as 200% or more as little as 5% based on the change in diffusion rate of the signaling aptamer to the electrode compared to the signaling aptamer when it is bound to the anchor aptamer. Signal gain is also measured above a baseline signal, and changing signaling aptamer concentration can therefore be used to tune the signal gain.
- Example 1 The experiment of Example 1 was repeated but instead of using mercaptohexanol passivation of the gold electrodes 650 , 652 , endogenous small molecule solutes found in blood or interstitial fluid were allowed to passivate the gold electrode 650 , 652 . It was found that without passivation background current was very high, but that both mercaptohexanol and endogeneous solutes were able to adequately reduce background current and enable sensor operation.
- the cortisol can diffuse into the sensor fluid and reach 90% of its concentration in the sample fluid in less than 20 minutes.
- a membrane that is 1.66% or 50% porous to cortisol and the lag time becomes 60 min or as little as 4 min, respectively.
- Aptamer concentration can be increased or decreased to adjust this lag time, the distance between the membrane and electrode and/or substrate can be modified to adjust this lag time by adjusting the sensor fluid volume, and for different analytes a higher or lower analyte concentration will also adjust this lag time (e.g.
- cortisol at 1 nM will have 10 ⁇ greater lag time while cortisol at 100 nM would have 10 ⁇ lesser lag time. Therefore generally, the present invention can enable devices with lag times to reach 90% of sensor response that are less than at least one of 180 min, 60 min, 20 min, 5 min, 2 min.
- Example 4 illustrates that a smaller sensor fluid volume is advantageous to achieve short lag times.
- a smaller sensor fluid volume may also allow one to keep the lag time constant but to reduce the sensor fluid volume down in a matter that allows the membrane porosity to decrease proportionally as well such that device performance such as longevity (aptamer isolation from sample fluid) is improved.
- Small volumes for the sensor fluids can be achieved in one or more ways and applied to planar or wire electrode formats.
- a gold electrode can be coated with a sugar solution (sucrose or trehalose) or a water soluble polymer such as poly-vinyl-alcohol containing the aptamers and dried to a solid film coating on the gold electrode.
- the membrane can be solution case using a solvent or fluid system that does not dissolve the solid-coated layer containing aptamer (for example alkanes to dissolve acrylic or styrene, or flourosolvents to dissolve Teflon, where they are cast and rapidly dried to create porosity).
- aptamer for example alkanes to dissolve acrylic or styrene, or flourosolvents to dissolve Teflon, where they are cast and rapidly dried to create porosity.
- the cast membranes can also contain dispersions of water soluble polymer or water soluble materials, such that when the membrane is coated and dried, when the device is wetted with water or sample fluid all the water soluble materials dissolve away, including the sugar used to coat the aptamers.
- the present invention may use orthogonal solvent systems (e.g., water and oil) to allow layer by layer fabrication of as solid aptamer layer and membrane that become filled with solution during use of the device with a sample fluid.
- the membrane can be deposited from a gas such as spray coating of nano beads or electrospinning, and the solid layer containing aptamer again is not harmed by fabrication of the membrane.
- the space between the membrane and the electrode or the substrate the electrode is fabricated on can also be regulated by one or more spacer materials, such as monodisperse spacer balls that are coated along with the aptamer and sugar layer.
- silica nanoparticles can be purchased in sizes ranging from 20 nm to 1 ⁇ m, and microbeads up to 10 or even 100 ⁇ M. Therefore, the present invention includes at least one method to fabricate a solid layer of aptamer that becomes a fluid during use and onto that solid layer of aptamer the membrane is coated. Therefore, the present invention enables a spacing between the electrode and the membrane that is at least one of less than 100 ⁇ m, 10 ⁇ m, 1 ⁇ m, 0.1 ⁇ m, or 0.01 ⁇ m.
- An embodiment of the present invention includes a sensor where the working electrode area is equal to the membrane area and as taught in other embodiments, the thickness of the sensor fluid is 5 ⁇ m.
- the membrane has an area of 0.2 ⁇ 0.2 cm or 0.04 cm 2 and the working electrode an area of 0.02 ⁇ 0.02 cm or 0.0004 cm 2 , the lifetime of the device therefore improves 100 ⁇ further while not sacrificing lag-time because less aptamer and redox couple would be interrogated due to the smaller working electrode area.
- the working electrode area and membrane area have a ratio of ⁇ 10, ⁇ 1, ⁇ 0.1, ⁇ 0.01 or ⁇ 0.001. This same approach can be used to reduce the sample volume by allowing the volume of the sensor fluid to be reduced further as the working electrode is further reduced.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Genetics & Genomics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Silicon Polymers (AREA)
Abstract
A sensing device for sensing at least one analyte in a sample solution is provided. The device 100 includes a sensor fluid 18 including an aptamer, and the aptamer is configured to measure an analyte included in a sample fluid 14, the aptamer configured to freely diffuse in the sensor fluid. The device also includes at least one isolation element (e.g., membrane 136) retaining the aptamer in the sensor fluid. A method of fabrication of a sensing device for sensing at least one analyte in a sample solution is provided. The method includes defining a volume 130 configured to house a sample fluid with at least one analyte, measuring an analyte included in a sensor fluid that is at least in part measured by an aptamer freely diffusing in the sensor fluid, and retaining the aptamer in the sensor fluid with at least one isolation element. A method of sensing an analyte in a sample fluid is also provided. The method includes bringing an analyte included in a sample fluid into contact with an aptamer included in a sensor fluid, resulting in a change in the electron transfer between a redox tag and an electrode, and measuring the change in electron transfer between the redox tag and the electrode.
Description
- This application claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/082,834, filed on Sep. 24, 2020; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/082,999, filed on Sep. 24, 2020; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/083,029, filed on Sep. 24, 2020; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/085,484, filed on Sep. 30, 2020; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/122,071, filed on Dec. 7, 2020; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/122,076, filed on Dec. 7, 2020; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/136,262, filed on Jan. 12, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,667, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,677, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,712, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,856, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,865, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,894, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,944, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,953, filed on Feb. 18, 2021; claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/150,986, filed on Feb. 18, 2021; and claims the benefit of the filing date of U.S. Patent Application Ser. No. 63/197,674, filed on Jun. 7, 2021, the disclosures of each of which are incorporated by reference herein in their entireties.
- This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
- Electrochemical aptamer sensors can identify the presence and/or concentration of an analyte of interest via the use of an aptamer sequence that specifically binds to the analyte of interest. These sensors include aptamers attached to an electrode, wherein each of the aptamers has a redox active molecule (redox couple) attached thereto. The redox couple can transfer electrical charge to or from the electrode. When an analyte binds to the aptamer, the aptamer changes shape, bringing the redox couple closer to or further from, on average, the electrode. This results in a measurable change in electrical current that can be translated to a measure of concentration of the analyte.
- A major unresolved challenge for aptamer sensors (particularly those where the aptamers are bonded to the working electrode) is the lifetime of the sensors, especially for applications where continuous operation is required (“continuous” referring to multiple measurements over time by the same device). To date, it has been difficult to provide electrochemical aptamer sensors with a lifetime that allows continuous sensing to take place over an extended period of time. Furthermore, for aptamer sensors where the aptamer is bonded to the electrode, the flexibility of design is limited and often the sensitivity of the aptamer therefore suffers as a consequence.
- What is needed are devices and methods to simultaneously resolve challenges for aptamer sensors.
- Certain exemplary aspects of the invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be explicitly set forth below.
- Many of the drawbacks and limitations stated above can be resolved by creating novel and advanced interplays of chemicals, materials, sensors, electronics, microfluidics, algorithms, computing, software, systems, and other features or designs, in a manner that affordably, effectively, conveniently, intelligently, or reliably brings sensing technology into proximity with biofluid and analytes.
- Various aspects of the disclosed invention are directed to a sensing device, a method of fabricating a sensing device, and a method of sensing an analyte in a sample fluid. As mentioned, one aspect provides a sensing device for sensing an analyte in a sample fluid. The sensing device includes a sensor fluid including a plurality of aptamers, at least one or more of the aptamers being configured to sense an analyte included in a sample fluid (such as by binding thereto). In various embodiments, the aptamer is freely diffusing in the sensor fluid. The sensing device further includes at least one isolation element that retains the plurality of aptamers in the sensor fluid.
- In another embodiment, a method of fabricating a sensing device for sensing an analyte in a sample fluid is provided. The method includes defining a first volume configured to house a sample fluid with at least one analyte. The method further includes defining a second volume configured to house a sensor fluid, the sensor fluid including an analyte that is at least in part measured by an aptamer freely diffusing in the sensor fluid. The method further includes retaining the aptamer in the sensor fluid with at least one isolation element.
- In another embodiment, a method of sensing an analyte in a sample solution is provided. The method includes bringing an analyte included in a sample fluid into contact with an aptamer included in a sensor fluid while the aptamer is freely diffusing in the sensor fluid. The contact of the aptamer with the analyte results in a change in the electron transfer between a redox tag and an electrode. The method further includes measuring the change in electron transfer between the redox tag and the electrode.
- The objects and advantages of the disclosed invention will be further appreciated in light of the following detailed descriptions and drawings in which:
-
FIG. 1A is a cross-sectional view of a device in accordance with principles of the disclosed invention. -
FIG. 1B is a cross-sectional view of an alternate embodiment of a device in accordance with principles of the disclosed invention. -
FIG. 2A is a schematic showing a prior art portion of an aptamer sensor device having a passivating layer and an aptamer attached to an electrode. -
FIG. 2B is a schematic showing the aptamer and passivating layer portions of the aptamer sensor device ofFIG. 2A degrading over time. -
FIG. 3 is a schematic of yet another embodiment of a device in accordance with principles of the present invention. -
FIG. 4 is a graph showing the effect of a membrane in an aptamer sensor device on percentage of solute retention versus molecular weight of the solute. -
FIG. 5A is a schematic of yet another embodiment of a device in accordance with principles of the present invention. -
FIG. 5B is a schematic showing an alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention. -
FIG. 5C is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention. -
FIG. 5D is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention. -
FIG. 5E is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention. -
FIG. 6A is a schematic of yet another embodiment of a device in accordance with principles of the present invention. -
FIG. 6B is a schematic showing an alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention. -
FIG. 6C is a schematic showing yet another alternate embodiment of an aptamer with attached redox tag that can be used with devices in accordance with principles of the disclosed invention. -
FIG. 7 is a schematic of yet another embodiment of a device in accordance with principles of the present invention. -
FIG. 8 is a schematic of yet another embodiment of a device in accordance with principles of the present invention. -
FIG. 9 is a schematic of yet another embodiment of a device in accordance with principles of the present invention. -
FIG. 10A is a graph showing raw chronoamperometric scans of current versus time for cortisol in an exemplary device. -
FIG. 10B is a graph showing normalized current gain for three sensors versus concentration of cortisol. - As used herein, “continuous sensing” with a “continuous sensor” means a sensor that changes in response to changing concentration of at least one solute in a solution such as an analyte. Similarly, as used herein, “continuous monitoring” means the capability of a device to provide multiple measurements of an analyte over time.
- As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, pH, size, concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
- As used herein, the term “electrode” means any material that is electrically conductive such as gold, platinum, nickel, silicon, conductive liquid infused materials such as ionic liquids, PEDOT:PSS, conductive oxides, carbon, boron-doped diamond, nanotubes or nanowire meshes, or other suitable electrically conducting materials.
- As used herein, the term “blocking layer” or “passivating layer” means a homogeneous or heterogeneous layer of molecules on an electrode which alter the electrochemical behavior of the electrode. Examples include a monolayer of mercaptohexanol on a gold electrode or as another example natural small-molecule solutes in serum that form a layer on a carbon electrode.
- As used herein, the term “aptamer” means a molecule that undergoes a conformation or binding change as an analyte binds to the molecule, and which satisfies the general operating principles of the sensing method as described herein. Such molecules are, e.g., natural or modified DNA, RNA, or XNA oligonucleotide sequences, spiegelmers, peptide aptamers, and affimers. Modifications may include substituting unnatural nucleic acid bases for natural bases within the aptamer sequence, replacing natural sequences with unnatural sequences, or other suitable modifications that improve sensor function, but which behave analogous to traditional aptamers. Two or more aptamers bound together can also be referred to as an aptamer (i.e. not separated in solution). Aptamers can have molecular weights of at least 1 kDa, 10 kDa, or 100 kDa.
- As used herein, the term “redox tag” or “redox molecule” means any species such as small or large molecules with a redox active portion that when brought adjacent to an electrode can reversibly transfer at least one electron with the electrode. Redox tag or molecule examples include methylene blue, ferrocene, quinones, or other suitable species that satisfy the definition of a redox tag or molecule. In some cases, a redox tag or molecule is referred to as a redox mediator. Redox tags or molecules may also exchange electrons with other redox tags or molecules.
- As used herein, the term “change in electron transfer” means a redox tag whose electron transfer with an electrode has changed in a measurable manner. This change in electron transfer can, for example, originate from availability for electron transfer, distance from an electrode, diffusion rate to or from an electrode, a shift or increase or decrease in electrochemical activity of the redox tag, or any other embodiment as taught herein that results in a measurable change in electron transfer between the redox tag and the electrode.
- As used herein, the term “fluorescent tag” and “fluorescent quencher’ means molecules which are like those used in molecular beacon laboratory assays. Examples of fluorescent tags include 6-FAM (carboxylflourescien), JOE, TET, HEX, and examples of quenchers include black-hole quenchers, DABCYL.
- As used herein, the term “signaling aptamer” means an aptamer that is tagged with a redox active molecule or tag and/or contains a redox active portion itself and which provides a change in electrochemical signal when it is released from an anchor aptamer.
- As used herein, the term “anchor aptamer” means an aptamer that that can bind to a signaling aptamer, and when bound to the signaling aptamer changes at least one property of the bound vs. unbound signaling aptamer such as molecular weight, diffusion coefficient, charge state, being floating in solution vs. being immobilized, or some other property which achieves the stated effect for the signaling aptamer. The binding of the anchor aptamer with the signaling aptamer is dependent on concentration of the analyte to be measured.
- As used herein, the term “folded aptamer” means an aptamer that along its length associates with itself in one or more locations creating a three-dimensional structure for the aptamer that is distinct from an “unfolded aptamer” that is a freely floating and oscillating strand of aptamer. Aptamers can also be partially folded or partially unfolded in structure or in time spent in the folded vs. unfolded states. Multiple folding configurations are also possible.
- As used herein, the term “analyte” means any solute in a solution or fluid which can be measured using a sensor. Analytes can be small molecules, proteins, peptides, electrolytes, acids, bases, antibodies, molecules with small molecules bound to them, DNA, RNA, drugs, chemicals, pollutants, or other solutes in a solution or fluid.
- As used herein, the term “membrane” means a polymer film, plug of hydrogel, liquid-infused film, tiny pore, or other suitable material which is permiselective to transport of a solute through the membrane by solute parameters such as size, charge state, hydrophobicity, physical structure, or other solute parameters than can enable permiselectivity. For example, a dialysis membrane is permselective by passing small solutes but not large solutes such as proteins. Membranes as understood herein need not be multiporous, for example a nanotube or nanopore can act as a permiselective filter and is therefore considered part of a membrane as understood for the present invention.
- As used herein, the term “sample fluid” means any solution or fluid that contains at least one analyte to be measured.
- As used herein, the term “sensor fluid” means a solution or fluid that differs from a sample solution by at least one property, and through which the sensor solution and the sample solution are therefore separated but are in fluidic connection through at least one pathway such as a membrane. The sensor solution comprises at least one aptamer as a solute.
- As used herein, the term “reservoir fluid” means a solution or fluid that differs from a sample solution by at least one property, and through which the sensor solution and the reservoir solution are in fluidic connection through at least one pathway such as a membrane or a pin-hole connection. A reservoir fluid may have multiple function in a device, for example, by introducing a solute continuously or as needed by diffusion equilibrium into the sensor fluid, or for example removing unwanted solutes from a sensor fluid and acting as a “waste removal element”.
- As used herein, a “device” comprises at least one sensor based on at least one aptamer, at least one sensor solution, and at least one sample solution. Devices can sense multiple samples and be in multiple configurations such as a device to measure a pin-prick of blood, or a microneedle or in-dwelling sensor needle to measure interstitial fluid, or a device to measure saliva, tears, sweat, or urine sensor, or a device to measure water pollutants or food processing solutes, or other devices which measure at least one analyte found in a sample solution.
- One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, all features of an actual implementation may not be described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
- Certain embodiments of the disclosed invention show sensors as simple individual elements. It is understood that many sensors require two or more electrodes, reference electrodes, or additional supporting technology or features which are not captured in the description herein. Sensors are preferably electrical in nature, but may also include optical such as a LED or laser excitation source and a photodetector, chemical, mechanical, or other known biosensing mechanisms. Sensors can be in duplicate, triplicate, or more, to provide improved data and readings. Sensors may provide continuous or discrete data and/or readings. Certain embodiments of the disclosed invention show sub-components of what would be sensing devices with more sub-components needed for use of the device in various applications, which are known (e.g., a battery, antenna, adhesive), and for purposes of brevity and focus on inventive aspects, such components may not be explicitly shown in the diagrams or described in the embodiments of the disclosed invention. All ranges of parameters disclosed herein include the endpoints of the ranges.
- With reference to
FIGS. 1A and 1B , exemplary embodiments of devices in accordance with principles of the disclosed invention are shown. Referring first toFIG. 1A , adevice 100 is shown as being placed partially in-vivo into theskin 12 of a subject.Skin 12 includes the epidermis 12 a, thedermis 12 b, and the subcutaneous or hypodermis 12 c. Thedevice 100 includes afeature 112 that allows for access to sample fluids from the subject. Such sample fluids may include interstitial fluid (from thedermis 12 b) and/or blood (from a capillary 12 d). In the embodiment shown inFIG. 1A , thefeature 112 includes a plurality of microneedles (which may be formed of metal, polymer, semiconductor, glass, or other suitable material). Each of themicroneedles 112 projects from afirst substrate 108. And each microneedle 112 may include ahollow lumen 132. Thedevice 100 also includes a second substrate 110 (which may be a material such as polymer or glass) having anelectrode 150 adjacent thereto. Anoptional passivating layer 120 may be adjacent toelectrode 150, such thatelectrode 150 is positioned betweenpassivating layer 120 andsecond substrate 110.Passivating layer 120 includes a compound such as mercaptohexanol or may comprise natural solutes that have diffused into thedevice 100 from thedermis 12 b. - As can be seen in
FIG. 1A , a definedvolume 130 is present betweenfirst substrate 108 andpassivating layer 120. It will be recognized by those of ordinary skill in the art that definedvolume 130 does not necessarily have to be defined byfirst substrate 108 andpassivating layer 120—and in embodiments where passivating layer is absent,volume 130 may be defined byfirst substrate 108 andelectrode 150; or, alternatively, may be defined byfirst substrate 108 andsecond substrate 110. Asensor fluid 18 may be present within volume 130 (as shown inFIG. 1A ). Further, as can be seen in the embodiment ofFIG. 1A , at least onemembrane 136 is present betweenfirst substrate 108 andpassivating layer 120, and is positioned adjacentfirst substrate 108. The at least onemembrane 136 may be of various materials or substances—such as a dialysis membrane or hydrogel, for example. In the particular embodiment shown inFIG. 1A , portions of themembrane 136 overlie the boundary betweenvolume 130 andlumens 132 of each microneedle 112. Due to this positioning ofmembrane 136,volume 130 includessensor fluid 18, andlumens 132 includesample fluid 14—such as interstitial fluid fromdermis 12 b or blood fromcapillary 12 d. Together the total volume provided byvolume 130 andlumens 132 can be a microfluidic component such as channels, a hydrogel, or other suitable material. A diffusion or other fluidic pathway exists from thesample fluid 14, such as interstitial fluid or blood, intovolumes - Another embodiment of a
device 100 is shown inFIG. 1B . This embodiment also includes first andsecond substrates microneedles 112 havinglumens 132,electrode 150,passivating layer 120, definedvolume 130 and at least onemembrane 136. As can be seen fromFIG. 1B , in this embodiment,electrode 150 andpassivating layer 120 are recessed in second substrate 110 (as opposed to the configuration shown inFIG. 1A ). Thus,volume 130 is defined byfirst substrate 108 and combination ofsecond substrate 110 andpassivating layer 120. Further, the embodiment as shown inFIG. 1B includes a plurality ofmembranes 136, with eachmembrane 136 positioned in a distal end of eachlumen 132 of each microneedle 112. Due to this positioning ofmembranes 136, bothvolume 130 andlumens 132 include a sensor fluid 18 (and sample fluid is present in, and obtainable from, dermis 12 b and capillary 12 d, for example). - Alternative arrangements and materials to those discussed above with respect to
FIGS. 1A and 1B are possible, such as using a single needle or hydrogel polymer microneedles. In addition, one or more of the features ofdevice 100 or theentire device 100 could be implanted into the body and perform similarly as described herein. Furthermore, adevice 100 could be fully outside the body, if for example sampling a fluid such as sweat or tears. - Turning now to
FIGS. 2A and 2B , where like numerals refer to like features, a portion of aprior art device 200 is shown. Referring toFIG. 2A , an aptamer sensor includes a passivating or blocking layer 248 (including a compound such as mercaptohexanol) attached to an electrode 250 (made from a material such as gold), and having at least oneaptamer 270 that is attached to theelectrode 250, such as by being thiol-bonded to theelectrode 250. Theaptamer 270 has at least one redox tag ormolecule 240, such as methylene blue, associated therewith. Thedevice 200 is shown as being positioned in asample fluid 14, such as blood or interstitial fluid (for example). Thisprior art device 200 may have an analyte (not shown) that binds with theaptamer 270, thereby changing the availability of theredox tag 240 to theelectrode 250, such as by bringing it closer to, or further from, theelectrode 250. Conventional aptamer sensors can be limited in performance because an aptamer that is bound to an electrode often has a weaker binding affinity to an analyte than an aptamer that is free in solution. In addition, as shown inFIG. 2B , the sensors can degrade as theaptamer 270 and/or blockinglayer 248 degrades over time (e.g., chemical degradation, or detaching from the electrode 250). Also, because suchprior art devices 200 have relied on exogenous molecules (e.g., mercaptohexanol) for passivation, thepassivation layer 248 can also become thicker with fouling from solutes (such as albumin) in thesample fluid 14. - Thus, and with reference now to
FIG. 3 , where like numerals refer to like features, an embodiment of the disclosed invention that improves on the prior art devices and reduces or eliminates drawbacks with such devices is shown. To that end,FIG. 3 shows a device 300 (or at least a portion thereof) that includes anelectrode 350 and at least onemembrane 336 which separates asample fluid 14 from asensor fluid 18. Thesensor fluid 18 contains a plurality of aptamers 370 having redox tags 340. Theelectrode 350 may include apassivating layer 348. Thepassivating layer 348 may comprise one or moreendogeneous solutes 16 from thesample fluid 14 itself (or, as initially prepared, thepassivating layer 348 may be prepared from molecules that are known to be endogenous to the sample fluid to be tested). Examples of suchendogenous molecules 16 include small molecules such as amino acids, hormones, metabolites, or peptides. (Thus, thedevice 300 shown inFIG. 3 differs from that described above in prior artFIGS. 2A and 2B in that the prior art device described above included an aptamer and an exogenous molecule, such as mercaptohexanol. Similarly,electrode 350 could also contain apassivation layer 348 comprised, at least in part, by an exogenous molecule such as hexanethiol or mercaptohexanol. But, even in that case, the passivation layer could detach from theelectrode 350 and be in need of replacement.) By includingendogeneous molecules 16 in thepassivation layer 348, longer lifetime of thedevice 300 is achieved becauseendogenous molecules 16 can leave theelectrode 350 as shown byarrow 392 and anotherendogenous molecule 16 can replace that now-missing molecule as shown byarrow 390. Thus, in a sense, the very molecules in thesample fluid 14 can be used to “repair” the passivation layer as it degrades, thereby extending the life of the device. (As mentioned above, these endogenous molecules can originate from the sample fluid itself, be already present as a deliberate component of the sensor fluid, or could be a mix of the two.) As a non-limiting example,membrane 336 is able to pass in small solutes (e.g., <1 kDa)—for example, an analyte such as cortisol—and passivatingsolutes 16, such as amino-acids and peptides, but retains the aptamer 370 (with redox tag 340) which is often >10 kDa in molecular weight. If the aptamer 370 with redox tag 340 were not retained by themembrane 336, then aptamer 370 with redox tag 340 could be lost into the body and no longer able be able to provide a measurement of the analyte. - An example of the analysis of the use of a membrane to pass small solutes (small target analyte) while retaining aptamers within device is shown with reference to
FIG. 4 , which shows an illustrative plot of solute retention for a membrane such asmembrane 336. This is an example only, and shows that if measuring a small analyte such as cortisol (<400 Da) and using a large aptamer (>10 kDa or even >50 kDa) a membrane could be highly permeable to the analyte and poorly permeable to the aptamer. Thus, for example, in various embodiments, membranes of the present invention may have molecular weight cutoffs (i.e., the molecular weight above which a molecule will not easily pass through the membrane) that are at least one of <300 Da, <1000 Da, <3 kDa, <10 kDa, <30 kDa, <100 kDa, <300 kDa. Larger molecular weight cut-off membranes will require larger sized aptamers to prevent the aptamers from potentially escaping the device. - Several additional embodiments will be discussed below. In these additional embodiments, an increase in availability of the redox tag to the electrode can occur as a result of aptamer binding analyte, or, alternatively, without aptamer binding to an analyte. And even though each of the embodiments discussed below (and their respective figures) may show one specific example, the other the embodiments of the invention are not so limited (e.g., the various aptamer/redox tag types can be used across the various embodiments of devices disclosed herein, and vice versa.
- Turning now to
FIGS. 5A-5E , where like numerals refer to like features:FIG. 5A shows a portion of adevice 500 including asubstrate 510, asensor fluid 18, a plurality ofaptamers 570 withredox tags 540 free in thesensor fluid 18, apassivation layer 548 ofendogenous solutes 16, and an electrode adjacent thesubstrate 510. Though not part of the device,analytes 19 are also depicted as present in the sensor fluid of the device. The schematic shown inFIG. 5A also depicts an electron transfer event that occurs between aredox tag 540 and theelectrode 550. This is shown generally atreference numeral 598, and is a non-limiting example depicting thatelectron transfer 598 from aredox tag 540 occurs in an increased amount, or frequency, or rate, whenaptamer 570 binding toanalyte 19 occurs (e.g., as shown in the figure, when analyte is not bound to aptamer, the redox tag is not available—or is less available—to the electrode, due to, for example, a conformation of the aptamer that hinders or prevents such transfer when not bound to analyte; conversely, when aptamer binds analyte, the conformation of aptamer may change in a manner that positions the redox tag for electron transfer). In various embodiments, aptamer binding to analyte can provide changes in electron transfer and redox current (compared to baseline transfer and current—i.e., transfer/current in the absence of analyte binding) of greater than 5%, greater than 10%, greater than 20%, greater than 50%, greater than 100%, or greater than 200%. For the embodiments illustrated herein, non-limiting examples of electrical measurement techniques may include voltammetry, square wave voltammetry, amperometry, chronoamperometry, coulometry, chronocoulometry, with a preferred embodiment being square wave voltammetry. -
FIG. 5B schematically depicts another example of anaptamer 570 with attached redox tag 540 (that differs from theaptamer 570/redox tag 540 schematically shown inFIG. 5A ). The embodiment of theaptamer 570 inFIG. 5B is designed such that theredox tag 540 is more available for electron transfer with theelectrode 550 in the absence of anyanalyte 19 binding to the aptamer 570 (high electron transfer—or high ET). Conversely, whenanalyte 19 binds to theaptamer 570 ofFIG. 5B , theredox tag 540 is less available for electron transfer with the electrode 550 (e.g., theredox tag 540 is less exposed—low ET). -
FIG. 5C schematically depicts yet another example of an aptamer with attached redox tag 540 (that differs from theaptamer 570/redox tag 540 schematically shown inFIGS. 5A and 5B ). The embodiment shown inFIG. 5C is designed with two aptamer portions: a signalingaptamer 572 and ananchor aptamer 574. Aredox tag 540 is associated with (such as by being attached to) thesignaling aptamer 572. Theanchor aptamer 574 includes a portion that has affinity for, and thus can bind,analyte 19. Whenanalyte 19 is not bound to the anchor aptamer 574 (left side ofFIG. 5C ), the signalingaptamer 572 remains associated with theanchor aptamer 574, and so theredox tag 540 on signalingaptamer 572 is less available for electron transfer with the electrode 550 (low ET). However, once theanchor aptamer 574 binds to analyte 19 (right side ofFIG. 5C ), signalingaptamer 572 is released fromanchor aptamer 574, and theredox tag 540 becomes more available for electron transfer with the electrode 550 (high ET). It will be recognized that the device of the embodiment ofFIG. 5C has a plurality of aptamers—and thus includes a plurality of signalingaptamers 572, and a plurality ofanchor aptamers 574. As described above, each anchor aptamer of the plurality of anchor aptamers is adapted to bind to analyte. In one embodiment, each signaling aptamer of a majority of the plurality of signaling aptamers is bound to a respective anchor aptamer when a majority of anchor aptamers are not bound to any analyte. (This may occur, for example, prior to the introduction of any analyte.) Once analyte is introduced (such as when a sample fluid is introduced into the device—e.g., by being introduced into the sensor fluid of the device), at least a subset of anchor aptamers from the plurality of anchor aptamers then binds to analyte. When this occurs, a subset of signaling aptamers (from the total plurality of aptamers) dissociates from the anchor aptamers—and the redox tag becomes more available for electron transfer with the electrode. - Further, while the embodiment shown in
FIG. 5C depictsanalyte 19 binding toanchor aptamer 574 andredox tag 540 on signalingaptamer 572, in an alternate embodiment analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer). Even further configurations as possible, as understood by those skilled in the art of aptamers. To maximize the signal gain (change in signal) signalingaptamer 572 concentration will typically be less than or equal to theanchor aptamer 574 concentration else the signaling aptamer can cause increased background signal with or without the presence of analyte. -
FIG. 5D schematically depicts yet another example of an aptamer with attached redox tag 540 (that differs from the aptamers/redox tags schematically shown inFIGS. 5A, 5B, and 5C ). The embodiment of theaptamer 570 inFIG. 5D has both aredox tag 544 and aredox quencher 542 associated therewith (such as by being bound to the aptamer 570). Whenanalyte 19 is not bound to theaptamer 570, theredox tag 544 andredox quencher 542 are spatially separated (left side ofFIG. 5D ) thereby allowing for greater electron transfer betweenredox tag 544 and electrode 550 (high ET). However, once theaptamer 570 binds to analyte 19 (right side ofFIG. 5D ), theredox tag 544 andredox quencher 542 are brought into closer proximity with one another, thereby causing less electron transfer betweenredox tag 544 and electrode 550 (low ET). Numerous quenchers are possible, including anthraquinone-based redox molecules that can be self-quenching when two of such identical molecules are brought close together (monomer vs. dimer). -
FIG. 5E schematically depicts yet another example of an aptamer with attached redox tag 540 (that differs from the aptamers/redox tags schematically shown inFIGS. 5A, 5B, 5C , and 5D). The embodiment of theaptamer 570 inFIG. 5E has both afirst redox tag 546 and asecond redox tag 548 associated therewith (such as by being bound to the aptamer 570). Whenanalyte 19 is not bound to theaptamer 570, the first and second redox tags 546, 548 are spatially separated (left side ofFIG. 5E ) thereby allowing for greater electron transfer between first and second redox tags 546, 548 and electrode 550 (high ET). However, once theaptamer 570 binds to analyte 19 (right side ofFIG. 5E ), the first and second redox tags 546, 548 are brought closer together and the electron transfer from one of the redox tags 546, 548 to theelectrode 550 is altered due to a two-step mediated electron transfer process, or other effect, for two redox tags brought into close proximity. These changes in electron transfer are depicted in the voltammograms as shown as 546 a and 548 a. A non-limiting example of redox tags that enable the embodiment ofFIG. 5E include methylene blue and ferricyanide. - Turning now to
FIGS. 6A-6C , where like numerals refer to like features:FIG. 6A shows a portion of adevice 600 that includes asubstrate 610, at least first andsecond electrodes passivation layer 648 includingendogenous solutes 16, a sensor fluid 18 (which, in the embodiment illustrated inFIG. 6A is inside an optional hydrogel 638), a plurality ofaptamers 670 having redox tags 640 (free in solution), and a diffusion oriontophoretic pathway 694. Though not part of the device,analytes 19 are also depicted as present in the sensor fluid of the device.FIG. 6A also schematically depicts electron transfer that can occur betweenredox tags 640 and the first andsecond electrodes FIG. 6A , as a non-limiting example,electron transfer 698 from the redox tags 640 in an increased amount, or frequency, or rate, whenanalyte 19 is bound to theaptamer 670. For example, when analyte is bound to aptamer, the hydrodynamic radius or size of the aptamer is smaller and therefore providing a faster diffusion coefficient, which results in the redox tag being more available for electron transfer with the electrodes (such a version will be discussed in greater detail below with respect toFIG. 6B ); or, for example, when analyte is not bound to aptamer, the redox tag is not available—or is less available—to the electrode, due to, for example, a conformation of the aptamer that hinders or prevents such transfer when not bound to analyte; conversely, when aptamer binds analyte, the conformation of aptamer may change in a manner that positions the redox tag for electron transfer. In various embodiments, aptamer binding to analyte can provide changes in electron transfer and redox current (compared to baseline transfer and current—i.e., transfer/current in the absence of analyte binding) of greater than 5%, greater than 10%, greater than 20%, greater than 50%, greater than 100%, or greater than 200%. For the embodiments illustrated inFIGS. 6A-6C , non-limiting examples of electrical measurement techniques may include voltammetry, square wave voltammetry, amperometry, chronoamperometry, coulometry, chronocoulometry, with a preferred embodiment being amperometry. -
FIG. 6B schematically depicts another example of anaptamer 670 with attached redox tag 640 (that differs from theaptamer 670/redox tag 640 schematically shown inFIG. 6A ). The embodiment of the aptamer inFIG. 6B is designed such that theredox tag 640 is less available for electron transfer with theelectrodes FIG. 6B ), because of a longer diffusion time between the first andsecond electrodes analyte 19 binds to the aptamer 670 (right side ofFIG. 6B ), the hydrodynamic radius or size of the aptamer is smaller and therefore providing a faster diffusion coefficient, and thereforeredox tag 640 is more available for electron transfer with the first andsecond electrodes analyte 19 transforms theaptamer 670 between a long unfolded aptamer 670 (in the absence ofanalyte 19 binding) and anaptamer 670 with three stems whenanalyte 19 binds to aptamer 670. - As described above, with respect to
FIG. 6A , a non-limiting example of an environment within adevice 600 may include an optional hydrogel. In such an embodiment, the hydrogel 638 (such as agar or polyacrylamide) is added to further distinguish diffusion times betweenaptamers 670 bound toanalyte 19 andaptamers 670 not bound to analyte. This is because the hydrogel 638 creates a more tortuous and size-selective diffusion pathway than a pure fluid would by itself. For example, anaptamer 670 that fully dissociates could be modified to have a significant change in hydrodynamic radius (R), which changes its diffusion coefficient (D) according to D=kT/(6πηR). This equation is for diffusion in pure solution; a dense hydrogel 638 can be added to further distinguish the diffusion of the unfolded aptamer vs. the folded aptamer. The resulting current between the redox recycling electrodes is proportional as I∝DC/z, where C is the concentration of theaptamer 670 and z the electrode-to-electrode distance. With respect to changes in signal gain, the diffusion length of oligonucleotides (aptamers) varies with length to the ˜0.6th power, and a 15 kDa protein that is globular/unfolded can have a change in R of 2.15/3.65. -
FIG. 6C schematically depicts yet another example of anaptamer 670 with attached redox tag 640 (that differs from theaptamer 670/redox tag 640 schematically shown inFIGS. 6A and 6B ). The embodiment of the aptamer inFIG. 6C is designed with two aptamer portions: a signalingaptamer 672 and ananchor aptamer 674. Aredox tag 640 is associated with (such as by being attached to) thesignaling aptamer 672. Theanchor aptamer 674 includes a portion that has affinity for, and thus can bind,analyte 19. Whenanalyte 19 is not bound to the anchor aptamer 674 (left side ofFIG. 6C ), the signalingaptamer 672 remains associated with theanchor aptamer 674, and so theredox tag 640 on signalingaptamer 672 is less available for electron transfer with the first andsecond electrode 650, 652 (as the combined signaling andanchor aptamers anchor aptamer 674 binds to analyte 19 (right side ofFIG. 6C ), signalingaptamer 672 is released fromanchor aptamer 674, and theredox tag 640 becomes more available for electron transfer with the first andsecond electrodes 650, 652 (as theliberated signaling aptamer 672 will exhibit more rapid diffusion in sensor solution and hydrogel). Further, while the embodiment shown inFIG. 6C depictsanalyte 19 binding toanchor aptamer 674 andredox tag 640 on signalingaptamer 672, in an alternate embodiment analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer). - It will be recognized that when the device shown in
FIG. 6A uses the embodiment of aptamers ofFIG. 6C , it will include a plurality of signalingaptamers 672, and a plurality ofanchor aptamers 674. As described above, each anchor aptamer of the plurality of anchor aptamers is adapted to bind to analyte. In one embodiment, each signaling aptamer of a majority of the plurality of signaling aptamers is bound to a respective anchor aptamer when a majority of anchor aptamers are not bound to any analyte. (This may occur, for example, prior to the introduction of any analyte.) Once analyte is introduced (such as when a sample fluid is introduced into the device—e.g., by being introduced into the sensor fluid of the device), at least a subset of anchor aptamers from the plurality of anchor aptamers then binds to analyte. When this occurs, a subset of signaling aptamers (from the total plurality of aptamers) dissociates from the anchor aptamers—and the redox tag becomes more available for electron transfer with the electrode. - With further reference to
FIG. 6C , in addition to changes in diffusion coefficient, the larger the effective sphere for the aptamer the less likely it will experience electron transfer with an electrode (with a first principles estimation based on the inverse of sphere area, proportional to 1/R{circumflex over ( )}2). This example is simply to show that two factors can be at play for embodiments of the present invention, both distance of the redox tag to the electrode and diffusion time to/from the electrode. This diffusion time to an electrode applies other embodiments as well, where for example with a chronoamperometric response for an aptamer the total current baseline could remain higher or reach baseline more quickly as diffusion coefficient for the aptamers increases. This diffusion time to an electrode may also impact interrogation methods such as square wave voltammetry, as aptamer that is near the electrode can contribute to the signal as well if it is able to diffuse to the electrode during each square window (during each voltage pulse that is applied). The first andsecond electrodes - With reference to
FIG. 7 where like numerals refer to like features, another embodiment in accordance with aspects of the present invention is shown. As can be seen inFIG. 7 , a portion of adevice 700 is shown, and includes asubstrate 710, at least oneelectrode 750, apassivation layer 748 includingendogenous solutes 16, asensor fluid 18, a plurality of aptamers having redox tags 740 (free in the sensor solution), and a poorly-mobile ornon-mobile material 738 in thesensor fluid 18. Though not part of the device,analytes 19 are also depicted as present in the sensor fluid of the device. - The aptamers/redox tags component of the embodiment of
FIG. 7 is similar to that shown inFIGS. 5C and 6C , and includes two aptamer portions: a signalingaptamer 772 and ananchor aptamer 774. Aredox tag 740 is associated with (such as by being attached to) thesignaling aptamer 772. Theanchor aptamer 774 includes a portion that has affinity for, and thus can bind,analyte 19. As can be seen inFIG. 7 , theanchor aptamer 774 is immobilized vialinkage 739 to the poorly ornon-mobile material 738. The poorly-mobile ornon-mobile material 738 may comprise various materials, such as a hydrogel. In one non-limiting example, thematerial 738 could be a hydrogel such as polyacrylamide and the linker be a molecule such as acrydite that is attached to the anchor aptamer at a terminal end or other location. In an alternate embodiment, the anchor aptamer could be cross-linked with other anchor aptamers or the anchor aptamer made so large (e.g., >100 kDa) such that it is effectively immobile in adense hydrogel 738. - Still referring to
FIG. 7 , whenanalyte 19 is not bound to theanchor aptamer 774, the signalingaptamer 772 remains associated with theanchor aptamer 774, and so theredox tag 740 on signalingaptamer 772 is less available for electron transfer with the electrode 750 (because the combined signaling andanchor aptamers anchor aptamer 774 being linked to material 738). However, once theanchor aptamer 774 binds to analyte 19, the signalingaptamer 772 is released from anchor aptamer 774 (as indicated by arrow 796), and theredox tag 740 becomes more available for electron transfer with the electrode 750 (because theliberated signaling aptamer 772 will exhibit more rapid diffusion in sensor solution as it is no longer complexed with theanchor aptamer 774 that is linked to poorly-mobile or non-mobile material 738). Further, while the embodiment shown inFIG. 7 depictsanalyte 19 binding toanchor aptamer 774 andredox tag 740 on signalingaptamer 772, in an alternate embodiment analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer). - It will be recognized that the device of the embodiment of
FIG. 7 has a plurality of aptamers—and thus includes a plurality of signalingaptamers 772, and a plurality ofanchor aptamers 774. As described above, each anchor aptamer of the plurality of anchor aptamers is adapted to bind to analyte. In one embodiment, each signaling aptamer of a majority of the plurality of signaling aptamers is bound to a respective anchor aptamer when a majority of anchor aptamers are not bound to any analyte. (This may occur, for example, prior to the introduction of any analyte.) Once analyte is introduced (such as when a sample fluid is introduced into the device—e.g., by being introduced into the sensor fluid of the device), at least a subset of anchor aptamers from the plurality of anchor aptamers then binds to analyte. When this occurs, a subset of signaling aptamers (from the total plurality of aptamers) dissociates from the anchor aptamers—and the redox tag becomes more available for electron transfer with the electrode. - With reference to
FIG. 8 , where like numerals refer to like features, another embodiment in accordance with aspects of the present invention is shown. As can be seen inFIG. 8 , a portion of adevice 800 is shown, and includes asubstrate 810, at least oneelectrode 850, amembrane 838, asensor fluid 18, a plurality of aptamers having redox tags 740 (free in the sensor fluid). Though not part of the device,analytes 19 are also depicted as present in the sensor fluid of the device. The aptamers/redox tags component of the embodiment ofFIG. 8 is similar to that shown inFIGS. 5C, 6C, and 7 , and includes two aptamer portions: a signalingaptamer 882 and ananchor aptamer 884. Aredox tag 840 is associated with (such as by being attached to) thesignaling aptamer 882. Theanchor aptamer 884 includes a portion that has affinity for, and thus can bind,analyte 19. Themembrane 838 exhibits selective permeability based on size, charge, or at least one solute property, and is able to pass a signalingaptamer 882 but not a signaling aptamer that is attached to alarger anchor aptamer 884. Thus, themembrane 838 impacts the availability of theredox couple 840 to theelectrode 850. For example, a signaling aptamer could have a radius of 3 nm/2 nm in folded/unfolded states and an anchor aptamer have 27/7 nm in folded/unfolded state, creating a difference in size of ˜3-10× when a signaling aptamer is freed from an anchor aptamer. Nanofiltration membranes can provide 1s nM pore sizes, and ultrafiltration 10s to 100s nm pore sizes (PES, track-etch, and other materials), resulting in size selective permeability that would enable mainly only thesignaling aptamer 882 to penetrate the hydrogel ormembrane 838. - And so, still referring to
FIG. 8 , whenanalyte 19 is not bound to theanchor aptamer 884, the signalingaptamer 882 remains associated with theanchor aptamer 884, and so theredox tag 840 on signalingaptamer 882 is less available (or not available) for electron transfer with the electrode 850 (because thesignaling aptamer 882 will be unable to crossmembrane 838 due to being complexed with anchor aptamer 884). However, once theanchor aptamer 884 binds to analyte 19, the signalingaptamer 882 is released fromanchor aptamer 884 and is able to pass throughmembrane 838, resulting in theredox tag 840 becoming available for electron transfer with theelectrode 850. Further, while the embodiment shown inFIG. 8 depictsanalyte 19 binding toanchor aptamer 884 andredox tag 840 on signalingaptamer 882, in an alternate embodiment analyte binding may occur with signaling aptamer (signaling aptamer having redox tag), and binding of analyte to signaling aptamer may serve to release signaling aptamer from anchor aptamer (such as by change in conformation of signaling aptamer). - With reference to
FIG. 9 , where like numerals refer to like features, another embodiment in accordance with principles of the present invention is shown. In certain of the various embodiments discussed herein, a membrane is used to selectively allow passage of certain molecules and not of others. However, as no membrane is perfectly size selective, and as aptamers and redox tags can degrade over time, it may be advantageous to continually introduce a fresh supply of aptamers, signaling aptamers, and/or anchor aptamers or other solutes that increase performance of the sensor or improve longevity of the sensor (e.g. nuclease inhibitors, for example). Thus, as shown inFIG. 9 , a portion of adevice 900 includessubstrates 910, at least oneelectrode 950, amembrane 936, asample fluid 14, asensor fluid 18, and areservoir fluid 17. Themembrane 936 exhibits mass flow represented atreference numeral 991, and the device also includes a diffusion restrictive feature 935 (such as a pinhole or membrane) with a mass flow represented atreference numeral 993. - As a nonlimiting example of that shown in
FIG. 9 , consider a 0.2 kDa dialysis membrane formembrane 936 and assume the aptamers are 10-100× larger than the solute to be detected (e.g., phenylalanine, cortisol, etc.). Assume the system is designed such that the volume ofreservoir fluid 17 is at least one of 2×, 10×, 50×, or 250× greater than volume ofsensor fluid 18 and that themass flow 991 of aptamer is at least 2×, 10×, 50×, or 250× less thanmass flow 993 of aptamer, while themass flow 991 of the analyte is at least 2×, 10×, 50×, or 250× greater than themass flow 993 of the analyte. As a result, the concentrations of analyte will be within at least 50%, 10%, 2%, or 0.4% of each other when comparingsample fluid 14 withsensor fluid 18, and the concentrations of aptamer will be within at least 50%, 10%, 2%, or 0.4% of each other when comparingsensor fluid 18 andreservoir fluid 17. - As a geometrical example, consider a
membrane 936 with 0.2 cm2 area and 10% porosity to the analyte, and a diffusion restrictive feature 935 that is a pinhole inmaterials FIG. 9 . As a result, both analyte and aptamer concentrations can be maintained for prolonged periods of times (days, weeks, months) even if aptamer is lost from the device or degraded over time. Aptamers could also degrade over time and their presence in the device and the presence of other contaminants such as nucleases or proteins could be problematic. For example, if signaling aptamers became cleaved and their molecular weight decreased, they could give a false higher reading of signal in embodiments of the present invention. With membrane protection of the sensor fluid from the sample fluid, most degradation or contamination modes will be very slow, such that the reservoir may also act as a waste removal element. - With further reference to
FIG. 9 , various aspects of the present invention are taught in greater detail with respect to isolation of aptamer (or the plurality of aptamers) in thesensor fluid 18 from thesample fluid 14 andreservoir fluid 17. The principles described with respect toFIG. 9 apply broadly to other embodiments of devices disclosed herein. In that regard, consider an aptamer sensor for creatinine or phenylalanine, (which have molecular weight of only 131 Da and 165 Da, respectively), and an aptamer having a molecular weight of 10-15 kDa (which is common for many aptamers). In such a situation, amembrane 936 having a 150 Da molecular weight cutoff could be used to prevent movement of aptamers from sensor fluid to another fluid (like sensor fluid to sample fluid). Alternatively, commercial membranes such as Dow FilmTech Polyamide membranes with 200-400 Da cutoffs may be suitable for use asmembrane 936. Further still, non-limiting examples of alternate materials for themembrane 936 include cellulose acetate, polypiperazine-amide, and polydimethylsiloxane. But even in such a case, conventional membranes are designed for pressure-driven separations, and so include a significant thickness or a backing layer, which increases overall thickness (on the order of 100s of μM). A thick membrane (100's to 1000's of μm), such as these would impart a penalty on device response time to changes in analyte concentration, as the analyte must diffuse through the thick membrane (a thicker membrane 36 not only creates a more tortuous path for analyte diffusion, but it increases the distances over which the analyte concentration gradient exists between sample and sensor which further decreases the diffusive flux). Therefore, in one embodiment of the present invention the membrane backing material can be facing thesample fluid 14 to resolve this lag time increase at least in part because backing material typically has high porosity. - As an additional example, consider phenylalanine and a ˜90 nm thick
epoxy membrane 936 with an effective diffusion coefficient divided bymembrane 936 thickness of Deff/Δx of between about 5 m s−1×10−3 and 0.005 m s−1×10−3, as taught by Rodler et al. in Freestanding ultrathin films for separation of small molecules in an aqueous environment, Journal of Biotechnology, Volume 288, Dec. 20, 2018, pages 48-54. (https://doi.org/10.1016/j.jbiotec.2018.10.002). The thickness or porosity of themembrane 936 can be adjusted easily. Accordingly, the present invention may benefit from amembrane 936 that has a Deff/Ax of, in one embodiment, at least 5 m s−1×10−3. In another embodiment, the Deff/Ax is at least 0.5 m s−1×10−3. In yet another embodiment, the Deff/Ax is at least 0.05 m s−1×10−3. In another embodiment, the Deff/Ax is at least 0.005 m s−1×10−3.Membranes 936 of the present invention are, in one embodiment, less than about 100 nm thick. In another embodiment, membranes of the present invention are less than 1 μm thick. In yet another embodiment, membranes of the present invention are less than 10 μm thick. In another embodiment, membranes of the present invention are less than 100 μm thick. Amembrane 936 with a well-designed Deff/Δx of at least 5 m s−1×10−3 and thickness ofsensor fluid 18 of ˜1-10 μm, can enable a device on/off time for the sensor to measure 90% of the sample fluid concentration in at least <15 min. - Additionally, in some cases, the analyte molecular weight will become larger or be too large to permeate the
membrane 936, and the aptamer might permeate themembrane 936 due to its molecular weight or due to a stranded geometry that allows it to navigate through a membrane similar to a rope being pulled or pushed through a screen (if the rope were balled up, it could not be pushed through the screen). Therefore, alternate methods of isolating the aptamer fromsample fluid 14 are needed in some cases. One important factor is the retention % vs. molecular weight, (see the graph for amembrane 936 as illustrated inFIG. 4 ). This is also referred to as retentivity. Atypical membrane 936 can provide >90% retention for example at 10 kDa, and <9% retention at <1 kDa for a change in retentivity/change in molecular weight of ˜1×. This is not highly selective with respect to the present invention, because for example, with an implanted device, aptamers could be slowly and continually lost over time. Therefore, the present invention may benefit from a membrane with a change in retentivity/change in molecular weight that, in one embodiment, is at least 2×. In another embodiment, the membrane has a change in retentivity/change in molecular weight that is at least 5×. In yet another embodiment, the membrane has a change in retentivity/change in molecular weight that is at least 10×. In one embodiment, the membrane has a change in retentivity/change in molecular weight that is at least 20×. - Further, as taught in other embodiments, while some aptamer may be continually lost from the sensor fluid, fresh aptamer can diffuse in from an adjacent reservoir to replenish lost aptamer. This reservoir is shown in
FIG. 9 as includingreservoir fluid 17. As an example, the volume ofsensor fluid 18 could be 1 μL in volume using an area ofmembrane 936 of 0.1 cm2 and a separation distance betweenmembrane 936 andelectrode 950 of 0.01 cm (100 μm). A reservoir, includingreservoir fluid 17, which in turn includes fresh aptamer solution could be in fluid communication with the volume includingsensor fluid 18 via apore 995 that is only 0.001 cm2, such that analyte and aptamer would very slowly diffuse into/out of the aptamer reservoir, again, shown inFIG. 9 as includingreservoir fluid 17, but such that new aptamer would constantly diffuse into the volume including thesensor fluid 18 as any aptamer is lost from thesensor fluid 18 through themembrane 936 to thesample fluid 14. In one embodiment, thepore 995 is a fluidic connection from the reservoir, including thereservoir fluid 17, and the volume, including thesensor fluid 18. - Such an approach could allow for protein sensing. For example, assume a
sensor fluid 18 volume of 100 nL, and amembrane 936 that retains 90% of the aptamer over 6 hours, and which can allow a protein such as luteinizing hormone to diffuse into thesensor fluid 18 and achieve 90% ofsample fluid 14 concentration of the hormone within 12 hrs. This would allow adevice 900 to sufficiently measure luteinizing hormone for fertility monitoring applications. Now, if the reservoir includingreservoir fluid 17 with aptamer had a volume of 200 μL, then it could lose 10% of its aptamer before a sensor signal would be impacted by 10%. If thedevice 900 is losing aptamer through themembrane 936 at a rate of, for example, 10% of aptamer every 6 hours in the 100 nL volume includingsensor fluid 18, then with the 200 μL reservoir includingreservoir fluid 17, thedevice 900 could last 2000× longer or 12,000 hours or >16 months, more than long enough for creating animplantable device 900. Therefore, depending on the volume of the reservoir includingreservoir fluid 17 and scaling ofother device 900 dimensions andmembrane 936 porosity, the present invention can retain 90% of the initial aptamer concentration in thesensor fluid 18 for at least >16 months, >8 months, >4 months, >2 months, >1 month, >2 weeks or >1 week. - Further, and as will now be described in greater detail, there is no major penalty if the aptamer is designed such that one end of the aptamer is inactive and increases the total molecular weight of the aptamer by at least 50%. For example, in some embodiments, the aptamer includes an active end configured to bind to the analyte and which has the redox tag. In some embodiments, the aptamer may include a longer inactive end configured to provide molecular weight or size to the aptamer and/or configured to reduce aptamer permeation through the
membrane 936. The longer inactive end may be configured to be rigid or have at least one permanent fold, wherein the rigid aptamer or aptamer including a permanent fold is dimensionally larger than a non-rigid aptamer or aptamer not including a permanent fold. In one embodiment, the molecular weight of such aptamers is at least >15 kDa. In another embodiment, the molecular weight of such aptamers is at least >30 kDa. In yet another embodiment, the molecular weight of such aptamers is at least >60 kDa. In one embodiment, the molecular weight of such aptamers is at least >120 kDa. For example, that active end aptamer could have a molecular weight of at least <20, <10, or <5 kDa, and the inactive end of the aptamer may be configured to be folded and therefore configured to increase the total size and molecular weight of the aptamer. - In additional embodiments, aptamers may be attached to other materials, or to nanoparticles, to also help isolate them from the sample fluid. For example, an aptamer could be attached to a polyethylene glycol polymer, the polyethylene glycol polymer may have a molecular weight of about 300 kDa, which can be referred to as a ‘particle’. Particles could be other polymers, metal such as gold, carbon, or iron-oxide and can be, in different embodiments, at least >1 nm, >3 nm, >10 nm, >30 nm, or >100 nm in diameter and still stably dispersed in solution as is known using one or more methods like those used in the art of pigment and nanodispersions. Aptamers can be bound to iron nanoparticles using, as a non-limiting example, dibromomaleimide (DBM)-termination, and bound to gold nanoparticles using thiol termination. With use of magnetic nanoparticles such as iron-oxide, the aptamer isolation element may also be a magnet that retains the nanoparticles near the membrane with or without use of a membrane, and in this example the aptamer isolation element is a magnet. This approach could allow the present invention to measure a protein analyte, for example a 30 kDa protein with an average diameter of <5 nm.
- As described previously, the aptamers may be optically tagged aptamers having a fluorescent tag. In such embodiments, a fluorescence quencher may be used as well. For example, with reference to
FIG. 1 ,layer 120 could be a semi-transparent light source such as organic light emitting diode andelectrode 150 could be a light detector such as an inorganic photodiode facing the sample fluid with or without a light filter to increase signal to noise ratio. Aptamer could be tagged with a fluorescent optical tag that is excited by thelight source 120 and then emits light that is detected by theelectrode 150. Although not shown, the present invention may also include a fluorescence quencher that is tagged to the aptamer such as a black-hole quencher. In some embodiments, the analyte itself is the fluorescence quencher (e.g. NADH, FAD, elastin, collagen, tryptophan, keratin) by absorbing the energy from the fluorescence tag and emitting the light at a wavelength different than the fluorescence tag. - As anon-limiting example of the above, a typical optical aptamer probe is 25 nucleotides long. 15 of the nucleotides are complementary to or have a strong binding affinity for the analyte target and do not base pair with one another, while the five nucleotides at each terminus are complementary to each other rather than having strong affinity to the target analyte. A typical molecular beacon structure can be divided in 4 parts: 1) loop, an 18-30 base pair region that is complementary to or has strong binding affinity for the target analyte; 2) stem formed by the attachment to both termini of the loop of two short (5 to 7 nucleotide residues) oligonucleotides that are complementary to each other; 3) 5′ fluorophore at the 5′ end of the aptamer, a fluorescent dye is covalently attached; 4) 3′ quencher (non-fluorescent) dye that is covalently attached to the 3′ end of the aptamer. When the aptamer is in closed loop shape, the quencher resides in proximity to the fluorophore, which results in quenching the fluorescent emission of the latter. When the aptamer is open (e.g. caused by analyte binding) the fluorescence is not quenched. A closed loop structure is not required for the present invention, as the fluorescence tag and quencher can experience an average change in their distance with analyte binding, similar to that taught in previous embodiments of the present invention where a redox tag experiences an average change in distance to an electrode surface.
- Because passivating layers can degrade over time for blocking materials such as mercaptohexanol, in one embodiment the
sensor fluid 18 and/orreservoir fluid 17 contains a passivating solute such as peptides (e.g., albumin) that can continually re-attached to the electrode and support a long-lasting and predictable passivating layer. Although albumin may exist in thesample fluid 14, it may be unable to reach thesensor fluid 18 due to themembrane 936. - Although not illustrated in detail herein, the embodiments of the present invention may also be applied to a simple single-use device. For example,
device 100 ofFIG. 1 could be applied to theskin 12 and take a single measurement of an analyte within 15 minutes of application of thedevice 100 and then removed from theskin 12 surface. Alternately (not shown) a device format similar to a glucose test-strip or other device with a microfluidic channel or a wicking channel (like a lateral flow assay) can be used to transport a sample fluid to one or more sensors and embodiments as taught herein for the present invention. For example, the aptamers and redox tags could be dry and placed near the inlet of such a test strip and dissolved into the sample fluid and then transported to a membrane-protected working electrode where measurement of the analyte is performed. - With reference to
FIGS. 10A and 10B a cortisol binding aptamer was utilized in a manner similar to that taught inFIG. 6C , where thesignaling aptamer 672 was tagged with methylene blue as aredox tag 640 with an aptamer sequence of GTCGTCCCGAGAG [SEQ ID NO. 1] and where theanchor aptamer 674 with a sequence of ctctcgggacgacGCCCGCATGTTCCATGGATAGTCTTGACTAgtcgtccc [SEQ ID NO. 2]. -
Electrodes aptamers device 600 was measured amperometrically vs. a titration curve of cortisol as theanalyte 19. The results are shown inFIG. 10A andFIG. 10B (open circles, open diamonds, and solid diamonds), and a control experiment with titration of simply adding more cortisol but without aptamer in solution is also shown inFIG. 10B (solid circles). The signal gain in Example 1 is as much as 70%, and if the anchor aptamer was made even larger or smaller the signal gain could be tuned to be as much as 200% or more as little as 5% based on the change in diffusion rate of the signaling aptamer to the electrode compared to the signaling aptamer when it is bound to the anchor aptamer. Signal gain is also measured above a baseline signal, and changing signaling aptamer concentration can therefore be used to tune the signal gain. - The experiment of Example 1 was repeated but instead of using mercaptohexanol passivation of the
gold electrodes gold electrode - Sensors were tested with scanning wave voltammetry, and redox peaks via voltammetry were observable with 100 nM of aptamer. Higher aptamer concentrations only increase the amount of signal and 1 μM, and 10 μM and 100 μM of aptamer were tested as well. Generally, lower aptamer concentrations were preferred as they reduce device lag times as they require less concentration of analyte to create a change in sensor signal.
- Consider an example as shown in
FIG. 6C that teaches the impact of device parameters on device lag time. Assume a device that operates with a sample fluid that is interstitial fluid, where redox active interferents such as NADH/NAD+ (663 Da) are ˜20 nM each in serum (so 50 nM total). Diffusion coefficient is roughly proportional to the cube root of molecular weight. Accordingly, a 5 kDa aptamer would have diffusion coefficient that is 3× greater than NADH, and with the Cotrell equation, the current difference between NADH and the signaling aptamer would be 3{circumflex over ( )}(½) or 1.73×. Therefore to have 10× more current from signaling aptamer than NADH/NAD+ would require 50 nM*10*1.73=865 nM of aptamer. Next, round up and assume ˜1 μM of signaling aptamer to provide a safe margin on aptamer signal strength vs. interferents. If the distance between the membrane and electrode was 5 μm, then for cortisol at 10 nM and 1 μM aptamer the ‘equivalent’ volume of sensor fluid is 100× greater or 500 μm thick from a lag time perspective. Next, assume a membrane that is 10% porous to cortisol, for this configuration, the cortisol can diffuse into the sensor fluid and reach 90% of its concentration in the sample fluid in less than 20 minutes. Next, utilize a membrane that is 1.66% or 50% porous to cortisol, and the lag time becomes 60 min or as little as 4 min, respectively. Aptamer concentration can be increased or decreased to adjust this lag time, the distance between the membrane and electrode and/or substrate can be modified to adjust this lag time by adjusting the sensor fluid volume, and for different analytes a higher or lower analyte concentration will also adjust this lag time (e.g. cortisol at 1 nM will have 10× greater lag time while cortisol at 100 nM would have 10× lesser lag time. Therefore generally, the present invention can enable devices with lag times to reach 90% of sensor response that are less than at least one of 180 min, 60 min, 20 min, 5 min, 2 min. - Example 4 illustrates that a smaller sensor fluid volume is advantageous to achieve short lag times. A smaller sensor fluid volume may also allow one to keep the lag time constant but to reduce the sensor fluid volume down in a matter that allows the membrane porosity to decrease proportionally as well such that device performance such as longevity (aptamer isolation from sample fluid) is improved. Small volumes for the sensor fluids can be achieved in one or more ways and applied to planar or wire electrode formats. For example, a gold electrode can be coated with a sugar solution (sucrose or trehalose) or a water soluble polymer such as poly-vinyl-alcohol containing the aptamers and dried to a solid film coating on the gold electrode. Next, the membrane can be solution case using a solvent or fluid system that does not dissolve the solid-coated layer containing aptamer (for example alkanes to dissolve acrylic or styrene, or flourosolvents to dissolve Teflon, where they are cast and rapidly dried to create porosity). The cast membranes can also contain dispersions of water soluble polymer or water soluble materials, such that when the membrane is coated and dried, when the device is wetted with water or sample fluid all the water soluble materials dissolve away, including the sugar used to coat the aptamers. Generally, the present invention may use orthogonal solvent systems (e.g., water and oil) to allow layer by layer fabrication of as solid aptamer layer and membrane that become filled with solution during use of the device with a sample fluid. Alternately, the membrane can be deposited from a gas such as spray coating of nano beads or electrospinning, and the solid layer containing aptamer again is not harmed by fabrication of the membrane. The space between the membrane and the electrode or the substrate the electrode is fabricated on can also be regulated by one or more spacer materials, such as monodisperse spacer balls that are coated along with the aptamer and sugar layer. For example, silica nanoparticles can be purchased in sizes ranging from 20 nm to 1 μm, and microbeads up to 10 or even 100 μM. Therefore, the present invention includes at least one method to fabricate a solid layer of aptamer that becomes a fluid during use and onto that solid layer of aptamer the membrane is coated. Therefore, the present invention enables a spacing between the electrode and the membrane that is at least one of less than 100 μm, 10 μm, 1 μm, 0.1 μm, or 0.01 μm.
- With respect to an embodiment of the present invention, consider a device where lag-time and/or sample volume is a concern, because a high concentration of aptamer in the sensor solution can require a high amount of analyte that must diffuse from the sample fluid into the sensor fluid and the limiting factor for lifetime is fatigue of the redox tag (limited reversibility over time). An embodiment of the present invention includes a sensor where the working electrode area is equal to the membrane area and as taught in other embodiments, the thickness of the sensor fluid is 5 μm. In one embodiment, the membrane has an area of 0.2×0.2 cm or 0.04 cm2 and the working electrode an area of 0.02×0.02 cm or 0.0004 cm2, the lifetime of the device therefore improves 100× further while not sacrificing lag-time because less aptamer and redox couple would be interrogated due to the smaller working electrode area. In alternate embodiments, the working electrode area and membrane area have a ratio of <10, <1, <0.1, <0.01 or <0.001. This same approach can be used to reduce the sample volume by allowing the volume of the sensor fluid to be reduced further as the working electrode is further reduced.
- Although not described in detail herein, other steps which are readily interpreted from or incorporated along with the disclosed embodiments shall be included as part of the invention. The embodiments that have been described herein provide specific examples to portray inventive elements, but will not necessarily cover all possible embodiments commonly known to those skilled in the art.
Claims (59)
1. A sensing device for sensing at least one analyte comprising:
a sensor fluid including a plurality of aptamers, one or more aptamers of the plurality of aptamers being configured to sense an analyte included in a sample fluid, the plurality of aptamers configured to freely diffuse in the sensor fluid; and
at least one isolation element retaining the plurality of aptamers in the sensor fluid.
2. The device of claim 1 , wherein the isolation element is a membrane.
3. The device of claim 1 , wherein the one or more aptamers of the plurality of aptamers are configured to measure the analyte electrochemically and the one or more aptamers each includes at least one redox tag and the device includes at least one electrode.
4. The device of claim 1 , wherein the one or more aptamers of the plurality of aptamers are configured to measure the analyte optically and the one or more aptamers includes at least one fluorescent tag, at least one optical source, and at least one optical detector.
5. The device of claim 1 , further comprising a reservoir fluid that is in fluidic communication with the sensor fluid.
6. The device of claim 5 , wherein a volume of reservoir fluid is at least one of 2×, 10×, 50×, 250× greater than a volume of the sensor fluid.
7. The device of claim 5 , wherein a first mass flow of aptamer through the isolation element and a second mass flow of aptamer through a fluidic connection between the sensor fluid and the reservoir fluid, and the first mass flow is at least 2×, 10×, 50×, 250× less than the second mass flow.
8. The device of claim 5 , wherein there is a first mass flow of analyte through the isolation element and a second mass flow of analyte through a fluidic connection between the sensor fluid and the reservoir fluid, and the first mass flow is at least 2×, 10×, 50×, 250× greater than the second mass flow.
9. The device of claim 7 , wherein a concentration of aptamer in the sensor fluid is within at least 50%, 10%, 2%, 0.4% of the concentration in the reservoir fluid.
10. The device of claim 8 , where in the concentration of analyte in the sensor fluid is within at least 50%, 10%, 2%, 0.4% of the concentration in the sample fluid.
11. The device of claim 2 , wherein the membrane includes a backing material and the backing material is facing the sample fluid.
12. The device of claim 2 , wherein the membrane has a Deff/Δx that is greater than an amount selected from the group consisting of 5 m s−1×10−3, 0.5 m s−1×10−3, 0.05 m s−1×10−3, and 0.005 m s−1×10−3.
13. The device of claim 2 , wherein the membrane has a thickness that is less than an amount selected from the group consisting of ˜100 nm, 1 μm, 10 μm and 100 μm thick.
14. The device of claim 2 , wherein the membrane has a change in retentivity/change in molecular weight that is greater than an amount selected from the group consisting of 2×, 5×, 10×, and 20×.
15. The device of claim 5 , wherein the device is configured to retain 90% of the initial aptamer concentration in the sensor fluid for a period of time selected from the group consisting of >16 months, >8 months, >4 months, >2 months, >1 month, >2 weeks, and >1 week.
16. The device of claim 1 , wherein each aptamer of the plurality of aptamers includes at least an active portion and an inactive portion, the inactive portion comprising at least 50% of the total aptamer molecular weight.
17. The device of claim 16 , wherein the inactive portion of the aptamer is rigid by having a secondary structure wherein the aptamer is bound to itself.
18. The device of claim 16 , wherein the inactive portion of the aptamer includes at least one permanent fold.
19. The device of claim 16 , wherein the aptamer has a molecular weight that is an amount selected from the group consisting of >15 kDa, >30 kDa, or >60 kDa and >120 kDa.
20. The device of claim 16 , wherein the active portion of the aptamer has a molecular weight that is an amount selected from the group consisting of <20, <10, and <5 kDa.
21. The device of claim 1 , wherein a majority of the plurality of aptamers are bound to a plurality of nanoparticles.
22. The device of claim 21 , wherein the nanoparticles are magnetic and the isolation element is a magnet.
23. The device of claim 21 , wherein the size of the particles is selected from the group consisting of >1 nm, >3 nm, >10 nm, >30 nm, and >100 nm in diameter.
24. The device of claim 1 , wherein the analyte is a small molecule of molecular weight less than 1000 Da.
25. The device of claim 1 , wherein the analyte is a protein.
25. The device of claim 1 , wherein the sensor fluid includes at least one passivating solute.
26. The device of claim 1 , wherein the device is a continuous sensing device.
27. The device of claim 1 , wherein the device is a single-use device.
28. The device of claim 1 , wherein the device has a lag time, and the lag time to reach 90% of a sensor response is less than at least one of 180 min, 60 min, 20 min, 5 min, 2 min.
29. The device of claim 1 , wherein the device further comprises a surface opposite the isolation element, the surface defining a volume housing the sensor fluid and a distance between the surface and the element is at least one of less than 100 μm, 10 μm, 1 μm, 0.1 μm, 0.01 μm.
30. The device of claim 3 , wherein the electrode has an area and the membrane has an area, and the electrode area and membrane area have a ratio of <1, <0.1, <0.01 or <0.001.
31. The device of claim 3 , wherein a passivating layer is present on the electrode.
32. The device of claim 3 , wherein the redox tag is configured to move within the sensor fluid, and the movement of the redox tag results is a change of electron transfer between the redox tag and the electrode.
33. The device of claim 1 , wherein the plurality of aptamers comprise a plurality of signaling aptamers and a plurality of anchor aptamers.
34. The device of claim 33 , wherein the plurality of redox tags are bound to the signaling aptamers, but are not bound to the anchor aptamers.
35. The device of claim 1 , wherein the aptamer is a folded aptamer.
36. The device of claim 1 , wherein the aptamer is an unfolded aptamer.
37. The device of claim 2 , wherein the membrane has a Deff/Δx of between about 5 m s−1×10−3 and 0.005 m s−1×10−3.
38. The device of claim 2 , wherein the membrane has a Deff/Δx that is at least 0.005 m s−1×10−3.
39. The device of claim 2 , wherein the device is configured to measure 90% of the sample fluid concentration in at least <15 min.
40. The device of claim 1 , wherein one or more aptamers of the plurality of aptamers is tagged with a fluorescent optical tag.
41. The device of claim 41 , further comprising a fluorescence quencher.
42. A method of fabricating a sensing device for at least one analyte comprising:
defining a first volume configured to house a sample fluid with at least one analyte;
defining a second volume configured to house a sensor fluid, the sensor fluid including an analyte that is at least in part measured by an aptamer freely diffusing in the sensor fluid;
retaining the aptamer in the sensor fluid with at least one isolation element.
43. The method of claim 42 , wherein the aptamer is coated as a solid layer and the isolation element is coated onto a solid layer including the aptamer.
44. The method of claim 43 , wherein spacer material is coated along with the aptamer in the solid layer.
45. The method of claim 42 , further comprising fabricating a solid aptamer layer and the isolation element with solvent systems that are orthogonal; and fabricating the isolation element configured to be filled with a solution during use of the device with a sample fluid.
46. The method of claim 42 , further comprising defining a reservoir configured to house a reservoir fluid, wherein the sensor fluid is in fluid communication with the reservoir.
47. The method of claim 42 , wherein the sensor fluid is in fluid communication with the reservoir via a pore.
48. The method of claim 42 , wherein the isolation element is a membrane.
49. The method of claim 42 further comprising housing an electrode in the second volume.
50. The method of claim 49 further comprising spacing the electrode and the isolation element at least one of less than 100 μm, 10 μm, 1 μm, 0.1 μm, or 0.01 μm apart.
51. A method of sensing an analyte in a sample solution, the method comprising:
bringing an analyte included in a sample fluid into contact with an aptamer included in a sensor fluid, the aptamer being freely diffusing in the sensor fluid, the contact of the aptamer with the analyte resulting in a change in the electron transfer between a redox tag and an electrode; and
measuring the change in electron transfer between the redox tag and the electrode.
52. The method of claim 51 , wherein the sample fluid is in fluid communication with the sensor fluid, and wherein the sensor fluid is in fluid communication with a reservoir fluid, the method further comprising:
flowing the aptamer from the sensor fluid to the sample fluid at a first rate; and
flowing the aptamer from the reservoir fluid to the sensor fluid at a second flow rate.
53. The method of claim 52 , wherein the first rate is at least 2×, 10×, 50×, or 250× less than the second rate.
54. The method of claim 51 , wherein the sample fluid is in fluid communication with the sensor fluid, and wherein the sensor fluid is in fluid communication with a reservoir fluid, the method further comprising:
flowing the analyte from the sensor fluid to the sample fluid at a first rate; and
flowing the analyte from the sensor fluid to the reservoir fluid at a second flow rate.
55. The method of claim 54 , wherein the first rate is at least at least 2×, 10×, 50×, or 250× greater than the second rate.
56. The method of claim 51 , wherein the analyte is a protein.
57. The method of claim 51 , wherein measuring a change in electron transfer between the redox tag and the electrode has a lag time, and the lag time to reach 90% of a sensor response is less than at least one of 180 minutes, 60 minutes, 20 minutes, 5 minutes, and 2 minutes.
58. The method of claim 51 , wherein the redox tag is attached to the aptamer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/027,394 US20230333043A1 (en) | 2020-09-24 | 2021-09-24 | Solute-phase aptamer sensing with aptamer isolation |
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063082834P | 2020-09-24 | 2020-09-24 | |
US202063083029P | 2020-09-24 | 2020-09-24 | |
US202063082999P | 2020-09-24 | 2020-09-24 | |
US202063085484P | 2020-09-30 | 2020-09-30 | |
US202063122071P | 2020-12-07 | 2020-12-07 | |
US202063122076P | 2020-12-07 | 2020-12-07 | |
US202163136262P | 2021-01-12 | 2021-01-12 | |
US202163150865P | 2021-02-18 | 2021-02-18 | |
US202163150677P | 2021-02-18 | 2021-02-18 | |
US202163150712P | 2021-02-18 | 2021-02-18 | |
US202163150986P | 2021-02-18 | 2021-02-18 | |
US202163150894P | 2021-02-18 | 2021-02-18 | |
US202163150856P | 2021-02-18 | 2021-02-18 | |
US202163150953P | 2021-02-18 | 2021-02-18 | |
US202163150944P | 2021-02-18 | 2021-02-18 | |
US202163150667P | 2021-02-18 | 2021-02-18 | |
US202163197674P | 2021-06-07 | 2021-06-07 | |
US18/027,394 US20230333043A1 (en) | 2020-09-24 | 2021-09-24 | Solute-phase aptamer sensing with aptamer isolation |
PCT/US2021/051859 WO2022066982A1 (en) | 2020-09-24 | 2021-09-24 | Solute-phase aptamer sensing with aptamer isolation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230333043A1 true US20230333043A1 (en) | 2023-10-19 |
Family
ID=80845790
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/027,394 Pending US20230333043A1 (en) | 2020-09-24 | 2021-09-24 | Solute-phase aptamer sensing with aptamer isolation |
US18/027,438 Pending US20240027392A1 (en) | 2020-09-24 | 2021-09-24 | Solute-phase electrochemical aptamer sensors for improved longevity and sensitivity |
US18/246,045 Pending US20230358737A1 (en) | 2020-09-24 | 2021-09-24 | Continuously chemically enhanced aptamer sensors |
US18/246,040 Pending US20230358736A1 (en) | 2020-09-24 | 2021-09-24 | Continuous sensing with adapters and aptamers |
US18/027,395 Pending US20230333096A1 (en) | 2020-09-24 | 2021-09-24 | Aptamer sensors with continuous solute passivation |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/027,438 Pending US20240027392A1 (en) | 2020-09-24 | 2021-09-24 | Solute-phase electrochemical aptamer sensors for improved longevity and sensitivity |
US18/246,045 Pending US20230358737A1 (en) | 2020-09-24 | 2021-09-24 | Continuously chemically enhanced aptamer sensors |
US18/246,040 Pending US20230358736A1 (en) | 2020-09-24 | 2021-09-24 | Continuous sensing with adapters and aptamers |
US18/027,395 Pending US20230333096A1 (en) | 2020-09-24 | 2021-09-24 | Aptamer sensors with continuous solute passivation |
Country Status (5)
Country | Link |
---|---|
US (5) | US20230333043A1 (en) |
EP (3) | EP4217722A4 (en) |
AU (2) | AU2021349939A1 (en) |
CA (2) | CA3193837A1 (en) |
WO (6) | WO2022066982A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12109032B1 (en) | 2017-03-11 | 2024-10-08 | Biolinq Incorporated | Methods for achieving an isolated electrical interface between an anterior surface of a microneedle structure and a posterior surface of a support structure |
US11045142B1 (en) | 2017-04-29 | 2021-06-29 | Biolinq, Inc. | Heterogeneous integration of silicon-fabricated solid microneedle sensors and CMOS circuitry |
GB2622909B (en) | 2020-07-29 | 2024-10-30 | Biolinq Incorporated | Continuous analyte monitoring system with microneedle array |
JP7341583B6 (en) | 2021-05-08 | 2023-09-29 | バイオリンク インコーポレイテッド | Fault detection for microneedle array-based continuous analyte monitoring devices |
WO2023205630A1 (en) * | 2022-04-18 | 2023-10-26 | Virginia Commonwealth University | Ion detection without optical interference from samples |
EP4510927A1 (en) * | 2022-04-19 | 2025-02-26 | University of Cincinnati | Multimode sensor integration onto needle-based sensing systems |
US20230358649A1 (en) * | 2022-05-09 | 2023-11-09 | Vector Laboratories, Inc. | Compositions and methods for removal of bound detection agents |
WO2024055110A1 (en) * | 2022-09-15 | 2024-03-21 | Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Et Genie, S.E.C. | Sensor, kit, and method for biomarker detection in saliva |
WO2024077326A1 (en) * | 2022-10-11 | 2024-04-18 | Nutromics Technology Pty Ltd | Methods and apparatus for determining the amount of an analyte in a fluid |
US20240310322A1 (en) * | 2023-03-16 | 2024-09-19 | Robert Bosch Gmbh | Diffusion-based electrochemical sensors |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002514913A (en) * | 1996-12-19 | 2002-05-21 | エール ユニバーシティ | Bioreactive allosteric polynucleotide |
DE69842134D1 (en) * | 1997-06-12 | 2011-03-31 | Clinical Micro Sensors Inc | ELECTRONIC METHOD AND DEVICE FOR DETECTING ANALYTES |
US6426231B1 (en) * | 1998-11-18 | 2002-07-30 | The Texas A&M University System | Analyte sensing mediated by adapter/carrier molecules |
AU775563B2 (en) * | 1999-05-14 | 2004-08-05 | Brandeis University | Nucleic acid-based detection |
US7700295B2 (en) * | 2000-12-28 | 2010-04-20 | Mds Sciex | Elemental analysis of tagged biologically active materials |
AUPR975201A0 (en) * | 2001-12-24 | 2002-01-24 | Unisearch Limited | Enzymatic redox labelling of nucleic acids |
US7452452B2 (en) * | 2002-04-29 | 2008-11-18 | The Trustees Of Boston College | Carbon nanotube nanoelectrode arrays |
US7460960B2 (en) * | 2002-05-10 | 2008-12-02 | Epitome Biosystems, Inc. | Proteome epitope tags and methods of use thereof in protein modification analysis |
US8423114B2 (en) * | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
US7780973B2 (en) * | 2003-12-15 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Method and device for minimally invasive implantation of biomaterial |
US20100173347A1 (en) * | 2007-04-02 | 2010-07-08 | Brook Michael A | Stabilized gold nanoparticles and methods of making the same |
RU2551365C2 (en) * | 2011-02-28 | 2015-05-20 | Вито Нв | New separator, electrochemical cell with new separator and application of new separator at electrochemical cell |
US20120263793A1 (en) * | 2011-04-14 | 2012-10-18 | Franco Vitaliano | Bio-nano-plasmonic elements and platforms |
GB201212902D0 (en) * | 2012-07-20 | 2012-09-05 | Univ Singapore | Combinatoric encoding methods for microarrays |
US9701998B2 (en) * | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9354195B2 (en) * | 2013-12-12 | 2016-05-31 | Intel Corporation | Highly selective coated-electrode nanogap transducers for the detection of redox molecules |
WO2015139022A1 (en) * | 2014-03-14 | 2015-09-17 | Northeastern University | Microfluidic system and method for real-time measurement of antibody-antigen binding and analyte detection |
US20180368743A1 (en) * | 2014-06-12 | 2018-12-27 | The Trustees Of Columbia University In The City Of New New York | Graphene-based nanosensor for identifying target analytes |
US10722160B2 (en) * | 2014-12-03 | 2020-07-28 | The Regents Of The University Of California | Non-invasive and wearable chemical sensors and biosensors |
US20180353748A1 (en) * | 2015-07-24 | 2018-12-13 | University Of Cincinnati | Reverse iontophoresis biosensing with reduced sample volumes |
CN105711017B (en) * | 2016-02-17 | 2018-10-16 | 复旦大学 | A kind of method for preparing polymeric micro-fluidic chip based on hydrogel 3D printing |
WO2017164982A1 (en) * | 2016-03-21 | 2017-09-28 | The Regents Of The University Of California | Real-time and continuous measurement in vivo using aptamer-based biosensors |
WO2017189122A1 (en) * | 2016-04-25 | 2017-11-02 | Eccrine Systems, Inc. | Eab biosensors for detecting sweat analytes |
EP3449247B1 (en) * | 2016-04-27 | 2021-03-31 | Quantum Biosystems Inc. | Systems and methods for measurement and sequencing of bio-molecules |
EP3311861A1 (en) * | 2016-10-18 | 2018-04-25 | Cook Medical Technologies LLC | Dialysate regenerating device |
WO2018081193A1 (en) * | 2016-10-25 | 2018-05-03 | Purdue Research Foundation | Conjugates for sensing |
US12085576B2 (en) * | 2017-12-22 | 2024-09-10 | University Of Cincinnati | Hybrid enzymatic aptamer sensors |
WO2019213520A1 (en) * | 2018-05-04 | 2019-11-07 | University Of Cincinnati | Membrane enhanced sensors |
US20210310057A1 (en) * | 2018-06-05 | 2021-10-07 | Valorisation-Recherche, Limited Partnership | Kinetically programmed systems and reactions for molecular detection |
WO2020069185A1 (en) * | 2018-09-26 | 2020-04-02 | University Of Virginia Patent Foundation | Multiplexed on-chip impedance cytometry system and method |
US20220025447A1 (en) | 2018-12-10 | 2022-01-27 | 10X Genomics, Inc. | Generating spatial arrays with gradients |
US20220088596A1 (en) * | 2019-01-11 | 2022-03-24 | University Of Cincinnati | Membrane-coupled continuous sensing systems |
US20250040836A1 (en) * | 2019-01-11 | 2025-02-06 | University Of Cincinnati | Continuous extraction and sensing of interstitial fluid |
-
2021
- 2021-09-24 WO PCT/US2021/051859 patent/WO2022066982A1/en active Application Filing
- 2021-09-24 WO PCT/US2021/051967 patent/WO2022067046A1/en unknown
- 2021-09-24 US US18/027,394 patent/US20230333043A1/en active Pending
- 2021-09-24 US US18/027,438 patent/US20240027392A1/en active Pending
- 2021-09-24 CA CA3193837A patent/CA3193837A1/en active Pending
- 2021-09-24 US US18/246,045 patent/US20230358737A1/en active Pending
- 2021-09-24 CA CA3193835A patent/CA3193835A1/en active Pending
- 2021-09-24 WO PCT/US2021/051919 patent/WO2022067015A1/en active Application Filing
- 2021-09-24 US US18/246,040 patent/US20230358736A1/en active Pending
- 2021-09-24 WO PCT/US2021/051879 patent/WO2022066992A1/en unknown
- 2021-09-24 EP EP21873484.6A patent/EP4217722A4/en active Pending
- 2021-09-24 WO PCT/US2021/051855 patent/WO2022066979A1/en active Application Filing
- 2021-09-24 AU AU2021349939A patent/AU2021349939A1/en active Pending
- 2021-09-24 EP EP21873476.2A patent/EP4217492A4/en active Pending
- 2021-09-24 WO PCT/US2021/051857 patent/WO2022066981A1/en active Application Filing
- 2021-09-24 US US18/027,395 patent/US20230333096A1/en active Pending
- 2021-09-24 EP EP21873522.3A patent/EP4217495A4/en active Pending
- 2021-09-24 AU AU2021350031A patent/AU2021350031A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240027392A1 (en) | 2024-01-25 |
CA3193837A1 (en) | 2022-03-31 |
EP4217722A1 (en) | 2023-08-02 |
EP4217492A1 (en) | 2023-08-02 |
WO2022066992A1 (en) | 2022-03-31 |
AU2021349939A1 (en) | 2023-05-04 |
EP4217495A4 (en) | 2024-03-27 |
US20230358737A1 (en) | 2023-11-09 |
EP4217722A4 (en) | 2024-02-14 |
US20230358736A1 (en) | 2023-11-09 |
EP4217495A1 (en) | 2023-08-02 |
AU2021350031A1 (en) | 2023-05-11 |
WO2022066982A1 (en) | 2022-03-31 |
EP4217492A4 (en) | 2024-03-27 |
WO2022067046A1 (en) | 2022-03-31 |
AU2021350031A9 (en) | 2024-08-08 |
CA3193835A1 (en) | 2022-03-31 |
WO2022066979A1 (en) | 2022-03-31 |
WO2022066981A1 (en) | 2022-03-31 |
US20230333096A1 (en) | 2023-10-19 |
WO2022067015A1 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230333043A1 (en) | Solute-phase aptamer sensing with aptamer isolation | |
Rackus et al. | Electrochemistry, biosensors and microfluidics: a convergence of fields | |
CN102753965B (en) | Detect analytes | |
Medina-Sánchez et al. | Nanomaterials and lab-on-a-chip technologies | |
US7964347B2 (en) | Labels for electronic detection of individual molecules and methods for their detection | |
TW201417889A (en) | Device and method for molecular enrichment | |
Kurita et al. | Miniaturized one-chip electrochemical sensing device integrated with a dialysis membrane and double thin-layer flow channels for measuring blood samples | |
Kiba et al. | Electrochemical detection of redox species flowing in a nitrocellulose membrane and application to quantitative immunochromatography | |
Parolo et al. | Based Electrodes for Nanoparticles Detection. | |
Jiao et al. | Ferrofluids transport in bioinspired nanochannels: Application to electrochemical biosensing with magnetic-controlled detection | |
Chen et al. | Development of microfluidic concentrator using ion concentration polarization mechanism to assist trapping magnetic nanoparticle-bound miRNA to detect with Raman tags | |
US20230333044A1 (en) | Solute-phase electrochemical aptamer sensors with rapid time-to-measurement | |
US20230333101A1 (en) | Continuous optical aptamer sensors | |
Li et al. | Potential of a simple lab-on-a-tube for point-of-care measurements of multiple analytes | |
KR101789043B1 (en) | Origami-based biosample concentration device | |
US9939435B2 (en) | Detection of biological molecules using surface plasmon field enhanced fluorescence spectroscopy (SPFS) combined with isotachophoresis (ITP) | |
Stefan-van Staden et al. | Biosensor Technology | |
US20230329600A1 (en) | Small volume aptamer sensing without solution impedance or analyte depletion | |
Karami et al. | Nanoparticles-based biosensor devices developed for point-of-care (POC) analyses of c-reactive protein (CRP) as the clinically important inflammatory biomarker | |
Crawford | Plasmonic Nanoplatforms for Sensing, Diagnostics, and Therapy | |
Desagani et al. | Electrochemical sensors | |
WO2022125168A1 (en) | Electrochemical aptamer sensors with aptamers bound adjacent to the electrode |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF CINCINNATI, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEIKENFELD, JASON CHARLES;REEL/FRAME:063042/0390 Effective date: 20230307 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |